{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "# Load environment variables from .env file\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "https://github.com/microsoft/autogen/blob/main/notebook/agentchat_groupchat_stateflow.ipynb - see here for examples of coder and paper summariser agent\n",
    "\n",
    "1. initialiser (GC manager)\n",
    "2. Coder - get papers API (why is it a coder)\n",
    "3. Execute the code? - human input \n",
    "4. Scientist read the papers and write a summary\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import autogen\n",
    "\n",
    "load_dotenv() \n",
    "\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import autogen\n",
    "import os\n",
    "\n",
    "# Get the API key from environment variable\n",
    "openai_api_key = os.environ.get(\"OPENAI_API_KEY\")\n",
    "\n",
    "# Load the config list from JSON\n",
    "config_list = autogen.config_list_from_json(\n",
    "    \"OA_config_list.json\",\n",
    "    filter_dict={\"model\": [\"gpt-3.5-turbo\"]}\n",
    ")\n",
    "\n",
    "# Add the API key to each config in the list\n",
    "for config in config_list:\n",
    "    config[\"api_key\"] = openai_api_key"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Registered use_pubmed_api function for agent: Moderator\n",
      "Registered use_pubmed_api function for agent: Scientific_Rational\n",
      "Registered use_pubmed_api function for agent: Safety_Assistant\n",
      "Registered use_pubmed_api function for agent: Target_Assessment\n"
     ]
    }
   ],
   "source": [
    "import tempfile\n",
    "from autogen.coding import LocalCommandLineCodeExecutor\n",
    "from autogen import GroupChat\n",
    "from APIs.pubmed import PubMedAPI # Import the PubMedAPI class for literature search\n",
    "\n",
    "\n",
    "pubmed_api =PubMedAPI(email=\"sanazkazemi@hotmail.com\") # for enterez to contact you if neccessary\n",
    "\n",
    "    # Add other database APIs as needed\n",
    "def use_pubmed_api(query, max_results=10):\n",
    "    \"\"\"\n",
    "        Search PubMed for scientific literature related to the given query.\n",
    "\n",
    "        This function should be used when you need to retrieve recent, peer-reviewed scientific \n",
    "        information from biomedical literature. It's particularly useful for:\n",
    "        - Finding evidence to support scientific claims\n",
    "        - Gathering information on recent advancements in a specific area of biomedical research\n",
    "        - Identifying key papers or authors in a particular field\n",
    "        - Checking the current state of knowledge on a specific topic\n",
    "\n",
    "        Use this function when:\n",
    "        - You need up-to-date, scientifically validated information\n",
    "        - You want to cite specific papers to support your arguments\n",
    "        - You need to explore the current research landscape on a topic\n",
    "\n",
    "        Do not use this function when:\n",
    "        - You need information from non-scientific sources\n",
    "        - The query is not related to biomedical or life sciences\n",
    "        - You require full-text articles (this API only provides abstracts)\n",
    "        - You need information from a specific paper (use DOI or PMID instead)\n",
    "        - You're looking for general knowledge that doesn't require scientific citation\n",
    "\n",
    "        Args:\n",
    "        query (str): The search query. Can include Boolean operators (AND, OR, NOT) and \n",
    "                    field tags (e.g., [Title], [Author], [Journal]).\n",
    "        max_results (int, optional): Maximum number of results to return. Default is 5.\n",
    "                                    Increasing this number will increase the API call duration.\n",
    "\n",
    "        Returns:\n",
    "        str: A formatted string containing details of the found papers, including titles, \n",
    "            authors, journal names, publication years, DOIs, and abstracts.\n",
    "\n",
    "        Example:\n",
    "        >>> result = use_pubmed_api(\"ACE inhibitors hypertension\", 3)\n",
    "        >>> print(result)\n",
    "        Title: Comparative Effectiveness of ACE Inhibitors and ARBs in Hypertension Treatment\n",
    "        Authors: Smith J, Johnson M, Williams R\n",
    "        Journal: Journal of Hypertension, 2023\n",
    "        DOI: 10.1000/jht.2023.1234\n",
    "        Abstract: This study compares the effectiveness of ACE inhibitors and ARBs in...\n",
    "\n",
    "        Note:\n",
    "        - This function makes real-time API calls to PubMed. Use it judiciously to avoid \n",
    "        overwhelming the server or exceeding usage limits.\n",
    "        - The results are based on PubMed's relevance ranking and may not always return \n",
    "        the most recent papers first.\n",
    "        - Always critically evaluate the returned information and cross-reference when necessary.\n",
    "        \"\"\"\n",
    "    \n",
    "    print(f\"PubMed API called with query: {query}, max_results: {max_results}\")\n",
    "    papers = pubmed_api.query(query, max_results)\n",
    "    print(f\"Retrieved {len(papers)} papers from PubMed\")\n",
    "    result = pubmed_api.format_results(papers)\n",
    "    print(\"PubMed API call completed\")\n",
    "    \n",
    "    return result\n",
    "    \n",
    "\n",
    "temp_dir = tempfile.TemporaryDirectory()\n",
    "executor = LocalCommandLineCodeExecutor(\n",
    "    timeout=10,  # Timeout for each code execution in seconds.\n",
    "    work_dir=temp_dir.name,  # Use the temporary directory to store the code files.\n",
    ")\n",
    "\n",
    "gpt4_config = {\n",
    "    \"cache_seed\": False,  # change the cache_seed for different trials\n",
    "    \"temperature\": 0,\n",
    "    \"config_list\": config_list,\n",
    "    \"timeout\": 120,\n",
    "}\n",
    "\n",
    "Moderator = autogen.UserProxyAgent(\n",
    "    name=\"Moderator\",\n",
    "    code_execution_config=False,\n",
    "    human_input_mode=\"NEVER\",\n",
    "    system_message=\"\"\"\n",
    "                    You are the Moderator. You receive prompts from the \n",
    "    human and coordinate the discussion between the other \n",
    "    agents. After receiving input from all agents, you summarize \n",
    "    and present the final output. You have access to a PubMed search function. \n",
    "    Use it to find relevant scientific literature when needed.\"\"\",)\n",
    "\n",
    "\n",
    "scientific_rational = autogen.AssistantAgent(\n",
    "    name=\"Scientific_Rational\",\n",
    "    llm_config=config_list[0],\n",
    "    system_message=\"\"\"You provide scientific reasoning and explanations for the given \n",
    "                    prompt using articles and evidence. You reference the sources and \n",
    "                    provide a summary of the key points. Use the search_pubmed function\n",
    "                    to find relevant scientific literature when needed.\"\"\",)\n",
    "\n",
    "\n",
    "safety_officer = autogen.AssistantAgent(\n",
    "    name=\"Safety_Assistant\",\n",
    "    system_message=\"\"\"You are the safety assistant. You ensure that the chosen drug target is safe for human use. \n",
    "                    You provide a safety assessment of the drug target and suggest any necessary modifications.Use the search_pubmed function\n",
    "                    to find relevant scientific literature when needed.\",)\n",
    "                     human_input_mode=\"NEVER\"\"\",\n",
    "    llm_config=config_list[0],\n",
    ")\n",
    "target_assessment = autogen.AssistantAgent(\n",
    "    name=\"Target_Assessment\",\n",
    "    llm_config=config_list[0],\n",
    "    system_message=\"\"\"You develop strategies to assess and evaluate the target or goal mentioned in the prompt. \n",
    "                    You Provide a detailed plan for the assessment and evaluation of the target.Use the search_pubmed function\n",
    "                    to find relevant scientific literature when needed.\"\"\",\n",
    ")\n",
    "\n",
    "literature_agent = autogen.AssistantAgent(\n",
    "    name=\"Literature_Agent\",\n",
    "    llm_config=config_list[0],\n",
    "    system_message=\"\"\"You provide relevant literature and references related to the prompt. \n",
    "                    You summarize the key points and provide a list of references.Use the search_pubmed function\n",
    "                    to find relevant scientific literature when needed.\"\"\",\n",
    ")\n",
    "\n",
    "def state_transition(last_speaker, groupchat):\n",
    "    print(f\"checking if {last_speaker.name} used the pubmed api...\")\n",
    "    if hasattr(last_speaker, 'last_function_call') and last_speaker.last_function_call:\n",
    "        if \"use_pubmed_api\" in last_speaker.last_function_call:\n",
    "            print(f\"{last_speaker.name} used the PubMed API\")\n",
    "            print(f\"Query: {last_speaker.last_function_call['use_pubmed_api']['args'][0]}\")\n",
    "            print(f\"Results: {last_speaker.last_function_call['use_pubmed_api']['return_value']}\")\n",
    "        else:\n",
    "            print(f\"{last_speaker.name} did not use the PubMed API\")\n",
    "\n",
    "    if last_speaker == Moderator:\n",
    "        return scientific_rational\n",
    "    elif last_speaker == scientific_rational:\n",
    "        return safety_officer\n",
    "    elif last_speaker == safety_officer:\n",
    "        return target_assessment\n",
    "    elif last_speaker == target_assessment:\n",
    "        return Moderator\n",
    "    else:\n",
    "        return None\n",
    "\n",
    "\n",
    "agent_list=[Moderator, scientific_rational, safety_officer, target_assessment]\n",
    "\n",
    "for agent in agent_list:\n",
    "    agent.register_function(\n",
    "        function_map = {\n",
    "            \"use_pubmed_api\": use_pubmed_api,\n",
    "        })\n",
    "    print(f\"Registered use_pubmed_api function for agent: {agent.name}\")\n",
    "    \n",
    "\n",
    "groupchat = autogen.GroupChat(\n",
    "    agents=agent_list,\n",
    "    messages=[],\n",
    "    max_round=30,\n",
    "    speaker_selection_method=state_transition,\n",
    "    send_introductions=True,\n",
    ")\n",
    "manager = autogen.GroupChatManager(groupchat=groupchat, llm_config=config_list[0])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[33mchat_manager\u001b[0m (to Moderator):\n",
      "\n",
      "Please provide a prompt to start the discussion.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[33mModerator\u001b[0m (to chat_manager):\n",
      "\n",
      "\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "checking if Moderator used the pubmed api...\n",
      "\u001b[32m\n",
      "Next speaker: Scientific_Rational\n",
      "\u001b[0m\n",
      "\u001b[33mScientific_Rational\u001b[0m (to chat_manager):\n",
      "\n",
      "It seems like there is a misunderstanding. I am an AI model trained by OpenAI programmed to act as the \"Scientific_Rational\" assistant. I provide scientific reasoning and explanations for the given prompt using articles and evidence. I reference the sources and provide a summary of the key points. However, I am not capable of running Python scripts or shell scripts as you mentioned. Please provide a relevant scientific topic or question, and I will do my best to provide an accurate and informed answer.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "checking if Scientific_Rational used the pubmed api...\n",
      "\u001b[32m\n",
      "Next speaker: Safety_Assistant\n",
      "\u001b[0m\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[32], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mmanager\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43minitiate_chat\u001b[49m\u001b[43m(\u001b[49m\u001b[43mModerator\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessage\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mPlease provide a prompt to start the discussion.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:1018\u001b[0m, in \u001b[0;36mConversableAgent.initiate_chat\u001b[0;34m(self, recipient, clear_history, silent, cache, max_turns, summary_method, summary_args, message, **kwargs)\u001b[0m\n\u001b[1;32m   1016\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1017\u001b[0m         msg2send \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mgenerate_init_message(message, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[0;32m-> 1018\u001b[0m     \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmsg2send\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrecipient\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msilent\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43msilent\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1019\u001b[0m summary \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_summarize_chat(\n\u001b[1;32m   1020\u001b[0m     summary_method,\n\u001b[1;32m   1021\u001b[0m     summary_args,\n\u001b[1;32m   1022\u001b[0m     recipient,\n\u001b[1;32m   1023\u001b[0m     cache\u001b[38;5;241m=\u001b[39mcache,\n\u001b[1;32m   1024\u001b[0m )\n\u001b[1;32m   1025\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m agent \u001b[38;5;129;01min\u001b[39;00m [\u001b[38;5;28mself\u001b[39m, recipient]:\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:655\u001b[0m, in \u001b[0;36mConversableAgent.send\u001b[0;34m(self, message, recipient, request_reply, silent)\u001b[0m\n\u001b[1;32m    653\u001b[0m valid \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_append_oai_message(message, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124massistant\u001b[39m\u001b[38;5;124m\"\u001b[39m, recipient)\n\u001b[1;32m    654\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m valid:\n\u001b[0;32m--> 655\u001b[0m     \u001b[43mrecipient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mreceive\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmessage\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrequest_reply\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msilent\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    656\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    657\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[1;32m    658\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMessage can\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mt be converted into a valid ChatCompletion message. Either content or function_call must be provided.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    659\u001b[0m     )\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:820\u001b[0m, in \u001b[0;36mConversableAgent.receive\u001b[0;34m(self, message, sender, request_reply, silent)\u001b[0m\n\u001b[1;32m    818\u001b[0m reply \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mgenerate_reply(messages\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mchat_messages[sender], sender\u001b[38;5;241m=\u001b[39msender)\n\u001b[1;32m    819\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m reply \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m--> 820\u001b[0m     \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mreply\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msender\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msilent\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43msilent\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:655\u001b[0m, in \u001b[0;36mConversableAgent.send\u001b[0;34m(self, message, recipient, request_reply, silent)\u001b[0m\n\u001b[1;32m    653\u001b[0m valid \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_append_oai_message(message, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124massistant\u001b[39m\u001b[38;5;124m\"\u001b[39m, recipient)\n\u001b[1;32m    654\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m valid:\n\u001b[0;32m--> 655\u001b[0m     \u001b[43mrecipient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mreceive\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmessage\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrequest_reply\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msilent\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    656\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    657\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[1;32m    658\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMessage can\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mt be converted into a valid ChatCompletion message. Either content or function_call must be provided.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    659\u001b[0m     )\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:818\u001b[0m, in \u001b[0;36mConversableAgent.receive\u001b[0;34m(self, message, sender, request_reply, silent)\u001b[0m\n\u001b[1;32m    816\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m request_reply \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mFalse\u001b[39;00m \u001b[38;5;129;01mor\u001b[39;00m request_reply \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mreply_at_receive[sender] \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mFalse\u001b[39;00m:\n\u001b[1;32m    817\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m\n\u001b[0;32m--> 818\u001b[0m reply \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgenerate_reply\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat_messages\u001b[49m\u001b[43m[\u001b[49m\u001b[43msender\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msender\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43msender\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    819\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m reply \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m    820\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39msend(reply, sender, silent\u001b[38;5;241m=\u001b[39msilent)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:1972\u001b[0m, in \u001b[0;36mConversableAgent.generate_reply\u001b[0;34m(self, messages, sender, **kwargs)\u001b[0m\n\u001b[1;32m   1970\u001b[0m     \u001b[38;5;28;01mcontinue\u001b[39;00m\n\u001b[1;32m   1971\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_match_trigger(reply_func_tuple[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtrigger\u001b[39m\u001b[38;5;124m\"\u001b[39m], sender):\n\u001b[0;32m-> 1972\u001b[0m     final, reply \u001b[38;5;241m=\u001b[39m \u001b[43mreply_func\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msender\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43msender\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mreply_func_tuple\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mconfig\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1973\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m logging_enabled():\n\u001b[1;32m   1974\u001b[0m         log_event(\n\u001b[1;32m   1975\u001b[0m             \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   1976\u001b[0m             \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mreply_func_executed\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1980\u001b[0m             reply\u001b[38;5;241m=\u001b[39mreply,\n\u001b[1;32m   1981\u001b[0m         )\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/groupchat.py:1052\u001b[0m, in \u001b[0;36mGroupChatManager.run_chat\u001b[0;34m(self, messages, sender, config)\u001b[0m\n\u001b[1;32m   1050\u001b[0m         iostream\u001b[38;5;241m.\u001b[39mprint(colored(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124mNext speaker: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mspeaker\u001b[38;5;241m.\u001b[39mname\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgreen\u001b[39m\u001b[38;5;124m\"\u001b[39m), flush\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m)\n\u001b[1;32m   1051\u001b[0m     \u001b[38;5;66;03m# let the speaker speak\u001b[39;00m\n\u001b[0;32m-> 1052\u001b[0m     reply \u001b[38;5;241m=\u001b[39m \u001b[43mspeaker\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgenerate_reply\u001b[49m\u001b[43m(\u001b[49m\u001b[43msender\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1053\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mKeyboardInterrupt\u001b[39;00m:\n\u001b[1;32m   1054\u001b[0m     \u001b[38;5;66;03m# let the admin agent speak if interrupted\u001b[39;00m\n\u001b[1;32m   1055\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m groupchat\u001b[38;5;241m.\u001b[39madmin_name \u001b[38;5;129;01min\u001b[39;00m groupchat\u001b[38;5;241m.\u001b[39magent_names:\n\u001b[1;32m   1056\u001b[0m         \u001b[38;5;66;03m# admin agent is one of the participants\u001b[39;00m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:1972\u001b[0m, in \u001b[0;36mConversableAgent.generate_reply\u001b[0;34m(self, messages, sender, **kwargs)\u001b[0m\n\u001b[1;32m   1970\u001b[0m     \u001b[38;5;28;01mcontinue\u001b[39;00m\n\u001b[1;32m   1971\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_match_trigger(reply_func_tuple[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtrigger\u001b[39m\u001b[38;5;124m\"\u001b[39m], sender):\n\u001b[0;32m-> 1972\u001b[0m     final, reply \u001b[38;5;241m=\u001b[39m \u001b[43mreply_func\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43msender\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43msender\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mreply_func_tuple\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mconfig\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1973\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m logging_enabled():\n\u001b[1;32m   1974\u001b[0m         log_event(\n\u001b[1;32m   1975\u001b[0m             \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   1976\u001b[0m             \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mreply_func_executed\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1980\u001b[0m             reply\u001b[38;5;241m=\u001b[39mreply,\n\u001b[1;32m   1981\u001b[0m         )\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:1340\u001b[0m, in \u001b[0;36mConversableAgent.generate_oai_reply\u001b[0;34m(self, messages, sender, config)\u001b[0m\n\u001b[1;32m   1338\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m messages \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m   1339\u001b[0m     messages \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_oai_messages[sender]\n\u001b[0;32m-> 1340\u001b[0m extracted_response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_generate_oai_reply_from_client\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m   1341\u001b[0m \u001b[43m    \u001b[49m\u001b[43mclient\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_oai_system_message\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mclient_cache\u001b[49m\n\u001b[1;32m   1342\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1343\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m (\u001b[38;5;28;01mFalse\u001b[39;00m, \u001b[38;5;28;01mNone\u001b[39;00m) \u001b[38;5;28;01mif\u001b[39;00m extracted_response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;28;01melse\u001b[39;00m (\u001b[38;5;28;01mTrue\u001b[39;00m, extracted_response)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/agentchat/conversable_agent.py:1359\u001b[0m, in \u001b[0;36mConversableAgent._generate_oai_reply_from_client\u001b[0;34m(self, llm_client, messages, cache)\u001b[0m\n\u001b[1;32m   1356\u001b[0m         all_messages\u001b[38;5;241m.\u001b[39mappend(message)\n\u001b[1;32m   1358\u001b[0m \u001b[38;5;66;03m# TODO: #1143 handle token limit exceeded error\u001b[39;00m\n\u001b[0;32m-> 1359\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[43mllm_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m   1360\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcontext\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmessages\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m-\u001b[39;49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m]\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mpop\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mall_messages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcache\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcache\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43magent\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\n\u001b[1;32m   1361\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1362\u001b[0m extracted_response \u001b[38;5;241m=\u001b[39m llm_client\u001b[38;5;241m.\u001b[39mextract_text_or_completion_object(response)[\u001b[38;5;241m0\u001b[39m]\n\u001b[1;32m   1364\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m extracted_response \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/oai/client.py:697\u001b[0m, in \u001b[0;36mOpenAIWrapper.create\u001b[0;34m(self, **config)\u001b[0m\n\u001b[1;32m    695\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    696\u001b[0m     request_ts \u001b[38;5;241m=\u001b[39m get_current_ts()\n\u001b[0;32m--> 697\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    698\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m APITimeoutError \u001b[38;5;28;01mas\u001b[39;00m err:\n\u001b[1;32m    699\u001b[0m     logger\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mconfig \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mi\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m timed out\u001b[39m\u001b[38;5;124m\"\u001b[39m, exc_info\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/autogen/oai/client.py:306\u001b[0m, in \u001b[0;36mOpenAIClient.create\u001b[0;34m(self, params)\u001b[0m\n\u001b[1;32m    304\u001b[0m     params \u001b[38;5;241m=\u001b[39m params\u001b[38;5;241m.\u001b[39mcopy()\n\u001b[1;32m    305\u001b[0m     params[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mFalse\u001b[39;00m\n\u001b[0;32m--> 306\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mparams\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    308\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/openai/_utils/_utils.py:277\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    275\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    276\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[0;32m--> 277\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/openai/resources/chat/completions.py:643\u001b[0m, in \u001b[0;36mCompletions.create\u001b[0;34m(self, messages, model, frequency_penalty, function_call, functions, logit_bias, logprobs, max_tokens, n, parallel_tool_calls, presence_penalty, response_format, seed, service_tier, stop, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[1;32m    609\u001b[0m \u001b[38;5;129m@required_args\u001b[39m([\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m], [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[1;32m    610\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mcreate\u001b[39m(\n\u001b[1;32m    611\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    641\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m NOT_GIVEN,\n\u001b[1;32m    642\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ChatCompletion \u001b[38;5;241m|\u001b[39m Stream[ChatCompletionChunk]:\n\u001b[0;32m--> 643\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    644\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/chat/completions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m    645\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    646\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[1;32m    647\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmessages\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    648\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    649\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfrequency_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    650\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunction_call\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    651\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunctions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    652\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogit_bias\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    653\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    654\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    655\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mn\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    656\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    657\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mpresence_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    658\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mresponse_format\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    659\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mseed\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    660\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    661\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstop\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    662\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    663\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    664\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    665\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    666\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    667\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    668\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    669\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    670\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    671\u001b[0m \u001b[43m            \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    672\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    673\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    674\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[1;32m    675\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    676\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mChatCompletion\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    677\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    678\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mChatCompletionChunk\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    679\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/openai/_base_client.py:1261\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[0;34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[0m\n\u001b[1;32m   1247\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mpost\u001b[39m(\n\u001b[1;32m   1248\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   1249\u001b[0m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1256\u001b[0m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m   1257\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ResponseT \u001b[38;5;241m|\u001b[39m _StreamT:\n\u001b[1;32m   1258\u001b[0m     opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[1;32m   1259\u001b[0m         method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[1;32m   1260\u001b[0m     )\n\u001b[0;32m-> 1261\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/openai/_base_client.py:942\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[0;34m(self, cast_to, options, remaining_retries, stream, stream_cls)\u001b[0m\n\u001b[1;32m    933\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mrequest\u001b[39m(\n\u001b[1;32m    934\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m    935\u001b[0m     cast_to: Type[ResponseT],\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    940\u001b[0m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m    941\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ResponseT \u001b[38;5;241m|\u001b[39m _StreamT:\n\u001b[0;32m--> 942\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    943\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    944\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43moptions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    945\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    946\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    947\u001b[0m \u001b[43m        \u001b[49m\u001b[43mremaining_retries\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mremaining_retries\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    948\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/openai/_base_client.py:973\u001b[0m, in \u001b[0;36mSyncAPIClient._request\u001b[0;34m(self, cast_to, options, remaining_retries, stream, stream_cls)\u001b[0m\n\u001b[1;32m    970\u001b[0m log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mSending HTTP Request: \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m, request\u001b[38;5;241m.\u001b[39mmethod, request\u001b[38;5;241m.\u001b[39murl)\n\u001b[1;32m    972\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 973\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    974\u001b[0m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    975\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_should_stream_response_body\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    976\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    977\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    978\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m httpx\u001b[38;5;241m.\u001b[39mTimeoutException \u001b[38;5;28;01mas\u001b[39;00m err:\n\u001b[1;32m    979\u001b[0m     log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mEncountered httpx.TimeoutException\u001b[39m\u001b[38;5;124m\"\u001b[39m, exc_info\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpx/_client.py:914\u001b[0m, in \u001b[0;36mClient.send\u001b[0;34m(self, request, stream, auth, follow_redirects)\u001b[0m\n\u001b[1;32m    906\u001b[0m follow_redirects \u001b[38;5;241m=\u001b[39m (\n\u001b[1;32m    907\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mfollow_redirects\n\u001b[1;32m    908\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(follow_redirects, UseClientDefault)\n\u001b[1;32m    909\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m follow_redirects\n\u001b[1;32m    910\u001b[0m )\n\u001b[1;32m    912\u001b[0m auth \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_build_request_auth(request, auth)\n\u001b[0;32m--> 914\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_auth\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    915\u001b[0m \u001b[43m    \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    916\u001b[0m \u001b[43m    \u001b[49m\u001b[43mauth\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mauth\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    917\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    918\u001b[0m \u001b[43m    \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    919\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    920\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    921\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m stream:\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpx/_client.py:942\u001b[0m, in \u001b[0;36mClient._send_handling_auth\u001b[0;34m(self, request, auth, follow_redirects, history)\u001b[0m\n\u001b[1;32m    939\u001b[0m request \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mnext\u001b[39m(auth_flow)\n\u001b[1;32m    941\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 942\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_redirects\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    943\u001b[0m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    944\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    945\u001b[0m \u001b[43m        \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhistory\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    946\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    947\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    948\u001b[0m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpx/_client.py:979\u001b[0m, in \u001b[0;36mClient._send_handling_redirects\u001b[0;34m(self, request, follow_redirects, history)\u001b[0m\n\u001b[1;32m    976\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m hook \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_event_hooks[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mrequest\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n\u001b[1;32m    977\u001b[0m     hook(request)\n\u001b[0;32m--> 979\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_single_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    980\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    981\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m hook \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_event_hooks[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpx/_client.py:1015\u001b[0m, in \u001b[0;36mClient._send_single_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m   1010\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\n\u001b[1;32m   1011\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAttempted to send an async request with a sync Client instance.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1012\u001b[0m     )\n\u001b[1;32m   1014\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m request_context(request\u001b[38;5;241m=\u001b[39mrequest):\n\u001b[0;32m-> 1015\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mtransport\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1017\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, SyncByteStream)\n\u001b[1;32m   1019\u001b[0m response\u001b[38;5;241m.\u001b[39mrequest \u001b[38;5;241m=\u001b[39m request\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpx/_transports/default.py:233\u001b[0m, in \u001b[0;36mHTTPTransport.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    220\u001b[0m req \u001b[38;5;241m=\u001b[39m httpcore\u001b[38;5;241m.\u001b[39mRequest(\n\u001b[1;32m    221\u001b[0m     method\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mmethod,\n\u001b[1;32m    222\u001b[0m     url\u001b[38;5;241m=\u001b[39mhttpcore\u001b[38;5;241m.\u001b[39mURL(\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    230\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    231\u001b[0m )\n\u001b[1;32m    232\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_httpcore_exceptions():\n\u001b[0;32m--> 233\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_pool\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mreq\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    235\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(resp\u001b[38;5;241m.\u001b[39mstream, typing\u001b[38;5;241m.\u001b[39mIterable)\n\u001b[1;32m    237\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m Response(\n\u001b[1;32m    238\u001b[0m     status_code\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mstatus,\n\u001b[1;32m    239\u001b[0m     headers\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mheaders,\n\u001b[1;32m    240\u001b[0m     stream\u001b[38;5;241m=\u001b[39mResponseStream(resp\u001b[38;5;241m.\u001b[39mstream),\n\u001b[1;32m    241\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    242\u001b[0m )\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/connection_pool.py:216\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    213\u001b[0m         closing \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_assign_requests_to_connections()\n\u001b[1;32m    215\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_close_connections(closing)\n\u001b[0;32m--> 216\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    218\u001b[0m \u001b[38;5;66;03m# Return the response. Note that in this case we still have to manage\u001b[39;00m\n\u001b[1;32m    219\u001b[0m \u001b[38;5;66;03m# the point at which the response is closed.\u001b[39;00m\n\u001b[1;32m    220\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, Iterable)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/connection_pool.py:196\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    192\u001b[0m connection \u001b[38;5;241m=\u001b[39m pool_request\u001b[38;5;241m.\u001b[39mwait_for_connection(timeout\u001b[38;5;241m=\u001b[39mtimeout)\n\u001b[1;32m    194\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    195\u001b[0m     \u001b[38;5;66;03m# Send the request on the assigned connection.\u001b[39;00m\n\u001b[0;32m--> 196\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mconnection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    197\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpool_request\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\n\u001b[1;32m    198\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    199\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m ConnectionNotAvailable:\n\u001b[1;32m    200\u001b[0m     \u001b[38;5;66;03m# In some cases a connection may initially be available to\u001b[39;00m\n\u001b[1;32m    201\u001b[0m     \u001b[38;5;66;03m# handle a request, but then become unavailable.\u001b[39;00m\n\u001b[1;32m    202\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    203\u001b[0m     \u001b[38;5;66;03m# In this case we clear the connection and try again.\u001b[39;00m\n\u001b[1;32m    204\u001b[0m     pool_request\u001b[38;5;241m.\u001b[39mclear_connection()\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/connection.py:101\u001b[0m, in \u001b[0;36mHTTPConnection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m     98\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_connect_failed \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[1;32m     99\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc\n\u001b[0;32m--> 101\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_connection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/http11.py:143\u001b[0m, in \u001b[0;36mHTTP11Connection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    141\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m Trace(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse_closed\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[1;32m    142\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_response_closed()\n\u001b[0;32m--> 143\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m exc\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/http11.py:113\u001b[0m, in \u001b[0;36mHTTP11Connection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    102\u001b[0m     \u001b[38;5;28;01mpass\u001b[39;00m\n\u001b[1;32m    104\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m Trace(\n\u001b[1;32m    105\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mreceive_response_headers\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request, kwargs\n\u001b[1;32m    106\u001b[0m ) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[1;32m    107\u001b[0m     (\n\u001b[1;32m    108\u001b[0m         http_version,\n\u001b[1;32m    109\u001b[0m         status,\n\u001b[1;32m    110\u001b[0m         reason_phrase,\n\u001b[1;32m    111\u001b[0m         headers,\n\u001b[1;32m    112\u001b[0m         trailing_data,\n\u001b[0;32m--> 113\u001b[0m     ) \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_receive_response_headers\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    114\u001b[0m     trace\u001b[38;5;241m.\u001b[39mreturn_value \u001b[38;5;241m=\u001b[39m (\n\u001b[1;32m    115\u001b[0m         http_version,\n\u001b[1;32m    116\u001b[0m         status,\n\u001b[1;32m    117\u001b[0m         reason_phrase,\n\u001b[1;32m    118\u001b[0m         headers,\n\u001b[1;32m    119\u001b[0m     )\n\u001b[1;32m    121\u001b[0m network_stream \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_network_stream\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/http11.py:186\u001b[0m, in \u001b[0;36mHTTP11Connection._receive_response_headers\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    183\u001b[0m timeout \u001b[38;5;241m=\u001b[39m timeouts\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mread\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m)\n\u001b[1;32m    185\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 186\u001b[0m     event \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_receive_event\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    187\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(event, h11\u001b[38;5;241m.\u001b[39mResponse):\n\u001b[1;32m    188\u001b[0m         \u001b[38;5;28;01mbreak\u001b[39;00m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_sync/http11.py:224\u001b[0m, in \u001b[0;36mHTTP11Connection._receive_event\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    221\u001b[0m     event \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_h11_state\u001b[38;5;241m.\u001b[39mnext_event()\n\u001b[1;32m    223\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m event \u001b[38;5;129;01mis\u001b[39;00m h11\u001b[38;5;241m.\u001b[39mNEED_DATA:\n\u001b[0;32m--> 224\u001b[0m     data \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_network_stream\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    225\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mREAD_NUM_BYTES\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[1;32m    226\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    228\u001b[0m     \u001b[38;5;66;03m# If we feed this case through h11 we'll raise an exception like:\u001b[39;00m\n\u001b[1;32m    229\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    230\u001b[0m     \u001b[38;5;66;03m#     httpcore.RemoteProtocolError: can't handle event type\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    234\u001b[0m     \u001b[38;5;66;03m# perspective. Instead we handle this case distinctly and treat\u001b[39;00m\n\u001b[1;32m    235\u001b[0m     \u001b[38;5;66;03m# it as a ConnectError.\u001b[39;00m\n\u001b[1;32m    236\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m data \u001b[38;5;241m==\u001b[39m \u001b[38;5;124mb\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_h11_state\u001b[38;5;241m.\u001b[39mtheir_state \u001b[38;5;241m==\u001b[39m h11\u001b[38;5;241m.\u001b[39mSEND_RESPONSE:\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/site-packages/httpcore/_backends/sync.py:126\u001b[0m, in \u001b[0;36mSyncStream.read\u001b[0;34m(self, max_bytes, timeout)\u001b[0m\n\u001b[1;32m    124\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_exceptions(exc_map):\n\u001b[1;32m    125\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sock\u001b[38;5;241m.\u001b[39msettimeout(timeout)\n\u001b[0;32m--> 126\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sock\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrecv\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmax_bytes\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/ssl.py:1233\u001b[0m, in \u001b[0;36mSSLSocket.recv\u001b[0;34m(self, buflen, flags)\u001b[0m\n\u001b[1;32m   1229\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m flags \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m0\u001b[39m:\n\u001b[1;32m   1230\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[1;32m   1231\u001b[0m             \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mnon-zero flags not allowed in calls to recv() on \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m%\u001b[39m\n\u001b[1;32m   1232\u001b[0m             \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__class__\u001b[39m)\n\u001b[0;32m-> 1233\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[43mbuflen\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1234\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1235\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28msuper\u001b[39m()\u001b[38;5;241m.\u001b[39mrecv(buflen, flags)\n",
      "File \u001b[0;32m~/anaconda3/envs/LLM_agent/lib/python3.12/ssl.py:1106\u001b[0m, in \u001b[0;36mSSLSocket.read\u001b[0;34m(self, len, buffer)\u001b[0m\n\u001b[1;32m   1104\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sslobj\u001b[38;5;241m.\u001b[39mread(\u001b[38;5;28mlen\u001b[39m, buffer)\n\u001b[1;32m   1105\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m-> 1106\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sslobj\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mlen\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1107\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m SSLError \u001b[38;5;28;01mas\u001b[39;00m x:\n\u001b[1;32m   1108\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m x\u001b[38;5;241m.\u001b[39margs[\u001b[38;5;241m0\u001b[39m] \u001b[38;5;241m==\u001b[39m SSL_ERROR_EOF \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39msuppress_ragged_eofs:\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "manager.initiate_chat(Moderator, message=\"Please provide a prompt to start the discussion.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Having heard from our team, we can outline a cohesive response:\n",
      "\n",
      "ACE inhibitors, crucial for conditions like hypertension and heart failure, have side effects ranging from a persistent dry cough to serious issues like renal dysfunction and angioedema (Mayo Clinic, MedlinePlus). \n",
      "\n",
      "The Safety_Assistant stressed the need for a comprehensive patient history, possible drug interactions, dose adjustments, and the contraindication of ACE inhibitors in pregnancy. Additional safety measures include educating the patient about potential side effects and actions required in case they occur, advising against unmonitored intake of potassium supplements, coordinating with other healthcare providers involved with the patient and arranging a clear workflow for patient monitoring and follow-up. Medication safety involves healthcare providers, scientific data, and direct patient participation in full circle.\n",
      "\n",
      "The Target_Assessment outlines a systematic strategy for evaluating ACE inhibitors safety, which includes analyzing patients' profiles, prescriptions, careful monitoring, and robust adverse event reporting systems. Furthermore, they suggest regularly updating healthcare professionals' knowledge on ACE inhibitors safety and effectiveness, and evaluating the outlined strategies by performing periodic audits.\n",
      "\n",
      "Therefore, while ACE inhibitors are an essential part of cardiovascular treatment, careful consideration of potential side effects, regular patient monitoring, and commitment to continuous understanding enhance their impacts towards safer and improved clinical outcomes.\n"
     ]
    }
   ],
   "source": [
    "print(chat_result.summary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "from APIs.pubmed import PubMedAPI # Import the PubMedAPI class for literature search\n",
    "\n",
    "def use_pubmed_api(query, max_results=10):\n",
    "    \"\"\"\n",
    "        Search PubMed for scientific literature related to the given query.\n",
    "\n",
    "        This function should be used when you need to retrieve recent, peer-reviewed scientific \n",
    "        information from biomedical literature. It's particularly useful for:\n",
    "        - Finding evidence to support scientific claims\n",
    "        - Gathering information on recent advancements in a specific area of biomedical research\n",
    "        - Identifying key papers or authors in a particular field\n",
    "        - Checking the current state of knowledge on a specific topic\n",
    "\n",
    "        Use this function when:\n",
    "        - You need up-to-date, scientifically validated information\n",
    "        - You want to cite specific papers to support your arguments\n",
    "        - You need to explore the current research landscape on a topic\n",
    "\n",
    "        Do not use this function when:\n",
    "        - You need information from non-scientific sources\n",
    "        - The query is not related to biomedical or life sciences\n",
    "        - You require full-text articles (this API only provides abstracts)\n",
    "        - You need information from a specific paper (use DOI or PMID instead)\n",
    "        - You're looking for general knowledge that doesn't require scientific citation\n",
    "\n",
    "        Args:\n",
    "        query (str): The search query. Can include Boolean operators (AND, OR, NOT) and \n",
    "                    field tags (e.g., [Title], [Author], [Journal]).\n",
    "        max_results (int, optional): Maximum number of results to return. Default is 5.\n",
    "                                    Increasing this number will increase the API call duration.\n",
    "\n",
    "        Returns:\n",
    "        str: A formatted string containing details of the found papers, including titles, \n",
    "            authors, journal names, publication years, DOIs, and abstracts.\n",
    "\n",
    "        Example:\n",
    "        >>> result = use_pubmed_api(\"ACE inhibitors hypertension\", 3)\n",
    "        >>> print(result)\n",
    "        Title: Comparative Effectiveness of ACE Inhibitors and ARBs in Hypertension Treatment\n",
    "        Authors: Smith J, Johnson M, Williams R\n",
    "        Journal: Journal of Hypertension, 2023\n",
    "        DOI: 10.1000/jht.2023.1234\n",
    "        Abstract: This study compares the effectiveness of ACE inhibitors and ARBs in...\n",
    "\n",
    "        Note:\n",
    "        - This function makes real-time API calls to PubMed. Use it judiciously to avoid \n",
    "        overwhelming the server or exceeding usage limits.\n",
    "        - The results are based on PubMed's relevance ranking and may not always return \n",
    "        the most recent papers first.\n",
    "        - Always critically evaluate the returned information and cross-reference when necessary.\n",
    "        \"\"\"\n",
    "    \n",
    "    print(f\"PubMed API called with query: {query}, max_results: {max_results}\")\n",
    "    papers = pubmed_api.query(query, max_results)\n",
    "    print(f\"Retrieved {len(papers)} papers from PubMed\")\n",
    "    result = pubmed_api.format_results(papers)\n",
    "    print(\"PubMed API call completed\")\n",
    "    \n",
    "    return result\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "expected ':' (255893913.py, line 1)",
     "output_type": "error",
     "traceback": [
      "\u001b[0;36m  Cell \u001b[0;32mIn[36], line 1\u001b[0;36m\u001b[0m\n\u001b[0;31m    def get_typed_annotation(annotation: Any, globalns: Dict[str, Any]) -> Any\u001b[0m\n\u001b[0m                                                                              ^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m expected ':'\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "The return type of the function 'use_pubmed_api' is not annotated. Although annotating it is optional, the function should return either a string, a subclass of 'pydantic.BaseModel'.\n",
      "The following parameters of the function 'use_pubmed_api' with default values are not annotated: 'max_results'.\n",
      "The return type of the function 'use_pubmed_api' is not annotated. Although annotating it is optional, the function should return either a string, a subclass of 'pydantic.BaseModel'.\n",
      "The following parameters of the function 'use_pubmed_api' with default values are not annotated: 'max_results'.\n",
      "The return type of the function 'use_pubmed_api' is not annotated. Although annotating it is optional, the function should return either a string, a subclass of 'pydantic.BaseModel'.\n",
      "The following parameters of the function 'use_pubmed_api' with default values are not annotated: 'max_results'.\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "import json\n",
    "import autogen\n",
    "import tempfile\n",
    "from autogen.coding import LocalCommandLineCodeExecutor\n",
    "from autogen import GroupChat\n",
    "from APIs.pubmed import PubMedAPI # Import the PubMedAPI class for literature search\n",
    "\n",
    "\n",
    "\n",
    "# Load environment variables from .env file\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n",
    "# Load the config list from JSON\n",
    "config_list = autogen.config_list_from_json(\n",
    "    \"OA_config_list.json\",\n",
    "    filter_dict={\"model\": [\"gpt-4-turbo\"]}\n",
    ")\n",
    "\n",
    "# Add the API key to each config in the list\n",
    "for config in config_list:\n",
    "    config[\"api_key\"] = openai_api_key\n",
    "\n",
    "\n",
    "pubmed_api =PubMedAPI(email=\"sanazkazemi@hotmail.com\") # for enterez to contact you if neccessary\n",
    "\n",
    "\n",
    "gpt3_config = {\n",
    "    \"cache_seed\": False,  # change the cache_seed for different trials\n",
    "    \"temperature\": 0,\n",
    "    \"config_list\": config_list,\n",
    "    \"timeout\": 120,\n",
    "}\n",
    "\n",
    "initialiser = autogen.UserProxyAgent(\n",
    "    name=\"Initialiser\",\n",
    "    human_input_mode=\"TERMINATE\",\n",
    ")\n",
    "\n",
    "Moderator = autogen.AssistantAgent(\n",
    "    name=\"Moderator\",\n",
    "    llm_config=config_list[0],\n",
    "    human_input_mode=\"\",\n",
    "    system_message=\"\"\"You are 'Moderator', overseeing the drug discovery process. \n",
    "                    ensure all aspects of the prompt are addressed, and synthesize a comprehensive final report. You will:\n",
    "                    Your role is to coordinate the discussion between specialized agents,  ensuring all aspects of the prompt are addressed.\n",
    "\n",
    "                    1. Analyze the given prompt and break it down into subtasks for each agent.\n",
    "                    2. Assign tasks to appropriate agents and manage their interactions.\n",
    "                    3. Ensure all required sections (scientific rationale, target assessment strategy, and safety assessment) are thoroughly covered.\n",
    "                    4. Compile and summarize the inputs from all agents into a cohesive final report.\n",
    "                    5. Ensure all claims are properly referenced and the report follows the specified format.\n",
    "                    6. Present the final output, including a complete list of references.\"\"\"\n",
    "                    )\n",
    "\n",
    "scientific_rational = autogen.AssistantAgent(\n",
    "    name=\"SAR\",\n",
    "    llm_config=config_list[0],\n",
    "\n",
    "    system_message=\"\"\"You are 'SAR', an expert in target discovery and clinical target rationale. Your role is to develop a comprehensive scientific rationale for the given target in the specified disease. \n",
    "\n",
    "    \n",
    "    You will:\n",
    "                    Formulate a working hypothesis based on the provided information.\n",
    "                    Analyze the clinical target rationale, focusing on human biology evidence.\n",
    "                    Evaluate the relevance of the target to the disease and its physiological processes.\n",
    "                    Assess genetic links, phenotypes, and clinical evidence related to the target.\n",
    "                    Identify challenges in the drug discovery program for this target.\n",
    "                    Suggest alternative indications for target modulators.\n",
    "                    Use the use_pubmed_api function TWICE to find and cite relevant scientific literature.\n",
    "                    Ensure your response covers all points requested in the prompt, with a minimum of 2000 words for the main rationale.\"\"\",)\n",
    "\n",
    "\n",
    "safety_officer = autogen.AssistantAgent(\n",
    "    name=\"SAFEA\",\n",
    "    system_message=\"\"\"You are 'SAFEA' an expert in safety when it comes to target discovery. Your role is to conduct a thorough safety assessment of the proposed drug target. You will:\n",
    "\n",
    "                    Evaluate target expression patterns and tissue specificity.\n",
    "                    Analyze potential species differences between humans and animal models.\n",
    "                    Assess on-target and off-target safety concerns, including peripheral risks.\n",
    "                    Evaluate the risk of exaggerated pharmacology and immunogenicity.\n",
    "                    Consider the impact of genetic polymorphisms on target function.\n",
    "                    Provide a comprehensive safety profile addressing all points in the prompt's safety assessment section\"\"\",\n",
    "    llm_config=config_list[0],\n",
    ")\n",
    "target_assessment = autogen.AssistantAgent(\n",
    "    name=\"TAG\",\n",
    "    llm_config=config_list[0],\n",
    "    system_message=\"\"\"You are 'TAG' a specialist in assessing targets for drug discovery. Your role is to develop and outline a comprehensive 1-year Target Assessment (TA) to Lead Identification (LI) plan for the proposed drug target. Your responsibilities include:\n",
    "\n",
    "                    Analyze and highlight key inflection points that will inform the project's feasibility.\n",
    "                    Assess the status of in-vitro platforms and translational in vivo models.\n",
    "                    Identify and describe what needs to be established in terms of platforms and models.\n",
    "                    Elaborate on the target's tractability and major challenges for advancement in a drug discovery portfolio.\n",
    "                    Discuss and propose potential biomarkers and readouts for efficacy and target engagement.\n",
    "                    Outline a high-level TA-LI plan, focusing on critical milestones and decision points.\n",
    "                    Evaluate the commercial viability and desirability of the proposed mode of action on the target in a clinical setting.\n",
    "                    Assess the advantages and disadvantages of different therapeutic modalities for tackling the target.\n",
    "                    Use the use_pubmed_api function to find relevant target assessment data and literature.\n",
    "                    Provide a concise yet comprehensive target assessment strategy addressing all points in the prompt's target assessment section, within a 500-word limit.\n",
    "\n",
    "                    Your assessment should be evidence-based, drawing from the latest research and industry best practices in target assessment. \n",
    "                    \n",
    "                    Be prepared to interact with other specialists to ensure a well-rounded evaluation of the target\"\"\",\n",
    "                    )\n",
    "\n",
    "    # literature_agent = autogen.AssistantAgent(\n",
    "    #     name=\"Literature_Agent\",\n",
    "    #     llm_config=config_list[0],\n",
    "    #     system_message=\"\"\"You provide relevant literature and references related to the prompt. \n",
    "    #                     You summarize the key points and provide a list of references.Use the use_pubmed_api function\n",
    "    #                     to find relevant scientific literature when needed.\"\"\",)\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "agent_list=[scientific_rational, safety_officer, target_assessment]\n",
    "\n",
    "    \n",
    "groupchat = GroupChat(\n",
    "    agents=[initialiser, Moderator, scientific_rational, safety_officer, target_assessment],\n",
    "    messages=[],\n",
    "    max_round=12,\n",
    "    speaker_selection_method=\"round_robin\",\n",
    "    send_introductions=True,\n",
    ")\n",
    "\n",
    "manager = autogen.GroupChatManager(\n",
    "    groupchat=groupchat,\n",
    "    llm_config=gpt3_config,)\n",
    "\n",
    "\n",
    "def use_pubmed_api(query: str , max_results=10):\n",
    "    \"\"\"\n",
    "        Search PubMed for scientific literature related to the given query.\n",
    "\n",
    "        This function should be used when you need to retrieve recent, peer-reviewed scientific \n",
    "        information from biomedical literature. It's particularly useful for:\n",
    "        - Finding evidence to support scientific claims\n",
    "        - Gathering information on recent advancements in a specific area of biomedical research\n",
    "        - Identifying key papers or authors in a particular field\n",
    "        - Checking the current state of knowledge on a specific topic\n",
    "\n",
    "        Use this function when:\n",
    "        - You need up-to-date, scientifically validated information\n",
    "        - You want to cite specific papers to support your arguments\n",
    "        - You need to explore the current research landscape on a topic\n",
    "\n",
    "        Do not use this function when:\n",
    "        - You need information from non-scientific sources\n",
    "        - The query is not related to biomedical or life sciences\n",
    "        - You require full-text articles (this API only provides abstracts)\n",
    "        - You need information from a specific paper (use DOI or PMID instead)\n",
    "        - You're looking for general knowledge that doesn't require scientific citation\n",
    "\n",
    "        Args:\n",
    "        query (str): The search query. Can include Boolean operators (AND, OR, NOT) and \n",
    "                    field tags (e.g., [Title], [Author], [Journal]).\n",
    "        max_results (int, optional): Maximum number of results to return. Default is 5.\n",
    "                                    Increasing this number will increase the API call duration.\n",
    "\n",
    "        Returns:\n",
    "        str: A formatted string containing details of the found papers, including titles, \n",
    "            authors, journal names, publication years, DOIs, and abstracts.\n",
    "\n",
    "        Example:\n",
    "        >>> result = use_pubmed_api(\"ACE inhibitors hypertension\", 3)\n",
    "        >>> print(result)\n",
    "        Title: Comparative Effectiveness of ACE Inhibitors and ARBs in Hypertension Treatment\n",
    "        Authors: Smith J, Johnson M, Williams R\n",
    "        Journal: Journal of Hypertension, 2023\n",
    "        DOI: 10.1000/jht.2023.1234\n",
    "        Abstract: This study compares the effectiveness of ACE inhibitors and ARBs in...\n",
    "\n",
    "        Note:\n",
    "        - This function makes real-time API calls to PubMed. Use it judiciously to avoid \n",
    "        overwhelming the server or exceeding usage limits.\n",
    "        - The results are based on PubMed's relevance ranking and may not always return \n",
    "        the most recent papers first.\n",
    "        - Always critically evaluate the returned information and cross-reference when necessary.\n",
    "        \"\"\"\n",
    "    \n",
    "    print(f\"PubMed API called with query: {query}, max_results: {max_results}\")\n",
    "    papers = pubmed_api.query(query, max_results)\n",
    "    print(f\"Retrieved {len(papers)} papers from PubMed\")\n",
    "    result = pubmed_api.format_results(papers)\n",
    "    print(\"PubMed API call completed\")\n",
    "    \n",
    "    return result\n",
    "\n",
    "# havent done it for moderator as it interferes with other specialist agents by suggesting tool call.\n",
    "# A few options - \n",
    "\n",
    "# Register the use_pubmed_api function for all agents\n",
    "for agent in agent_list:\n",
    "    autogen.agentchat.register_function(\n",
    "        f=use_pubmed_api,  \n",
    "        caller=agent,\n",
    "        executor=agent,\n",
    "        name=\"use_pubmed_api\",\n",
    "        description=\"\"\"\n",
    "        Search PubMed for scientific literature related to the given query.\n",
    "\n",
    "        This function should be used when you need to retrieve recent, peer-reviewed scientific \n",
    "        information from literature:\n",
    "        - Finding evidence to support scientific claims\n",
    "        - Gathering information on recent advancements in a specific area of biomedical research\n",
    "        - Identifying key papers or authors in a particular field\n",
    "        - Checking the current state of knowledge on a specific topic\n",
    "        - You need up-to-date, scientifically validated information\n",
    "        - You want to cite specific papers to support your arguments\n",
    "        - You need to explore the current research landscape on a topic\n",
    "\n",
    "        Returns: A formatted string containing details of the found papers, including titles, DOI, abstracts.\n",
    "        \"\"\"\n",
    "    )\n",
    "\n",
    "\n",
    "def process_message(message):\n",
    "    # Clear the group chat history\n",
    "    \n",
    "    #groupchat.messages.clear()\n",
    "    \n",
    "    # Initiate the chat using the initialiser\n",
    "    \n",
    "\n",
    "    \n",
    "    # Extract the full conversation from the groupchat messages\n",
    "    chat_history = groupchat.messages\n",
    "    \n",
    "    # Format the conversation\n",
    "    formatted_conversation = []\n",
    "    for msg in chat_history:\n",
    "        if msg['content'].strip():  # Only add non-empty messages\n",
    "            formatted_conversation.append({\n",
    "                'speaker': msg['name'],\n",
    "                'message': msg['content']\n",
    "            })\n",
    "    \n",
    "    return formatted_conversation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[33mInitialiser\u001b[0m (to chat_manager):\n",
      "\n",
      "You are a AI assistant with a background in drug discovery.\n",
      "\n",
      "    Given target: Integrase\n",
      "    Given disease: HIV 1 infection\n",
      "    Given mode of action: Dolutegravir is an HIV-1 antiviral agent. It inhibits HIV integrase by binding to the active site and blocking the strand transfer step of retroviral DNA integration in the host cell. The strand transfer step is essential in the HIV replication cycle and results in the inhibition of viral activity. Dolutegravir has a mean EC50 value of 0.5 nM (0.21 ng/mL) to 2.1 nM (0.85 ng/mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells.4\n",
      "\n",
      "    Context:\n",
      "    The current treatment for HIV-1 infection involves a combination of antiretroviral drugs to suppress viral replication and prevent the progression of the disease. Dolutegravir is a potent integrase inhibitor that has shown high efficacy in the treatment of HIV-1 infection. However, there is a need to develop a scientific rationale for the use of dolutegravir in the treatment of HIV-1 infection, highlighting the working hypothesis, clinical target rationale, and challenges for the drug discovery program related to the target.\n",
      "\n",
      "    Task 1: Develop a scientific rationale for Integrase in HIV 1 infection.\n",
      "\n",
      "    Highlight the working hypothesis for the clinical target rationale and human biology evidence by minimum 2000 words.\n",
      "\n",
      "    Describe as much as possible the evidence in humans or in human tissue that link the target, target space or approach to the pathogenesis of interest.\n",
      "    If known, also describe here the wanted mode of action with regards to desired clinical outcome.\n",
      "    Please avoid including only pre-clinical data in this section.\n",
      "\n",
      "    Use the following structure and provide a detailed description for each point:\n",
      "    - Working hypothesis:\n",
      "    - Create a detailed description of the following idea: Creating a new inhibitor for HIV-1 integrase that is more potent and has a higher barrier to resistance than dolutegravir.\n",
      "    - Is there are significant unmet medical need?\n",
      "    - Is it suitable for combination therapy?\n",
      "    - Which predictive biomarkers exist for the target related to the disease?\n",
      "        - Provide a detailed description of existing clinical relevant biomarkers.\n",
      "\n",
      "    - Clinical target rationale:\n",
      "    - How relevant is the target location to the disease biology?\n",
      "    - How it the target expression altered in human disease?\n",
      "    - How is the target involved in the physiological process relevant to the disease?\n",
      "    - Which phenotypes and genotypes were identified for the target?\n",
      "    - How is the genetic link between the target and the disease?\n",
      "    - Describe the evidence provided in clinics or by tools acting on the pathway where the target is involved.\n",
      "    - Which kind of target modulation is required to treat the disease?\n",
      "\n",
      "    - Challenges for the drug discovery program related to the target.\n",
      "    - Check the following idea for details on small molecule compounds: Creating a new inhibitor for HIV-1 integrase that is more potent and has a higher barrier to resistance than dolutegravir..\n",
      "    - Is a 'information driven approach' (IDA) strategy based on available small molecules possible?\n",
      "        - Which small molecular modulators of the target known?\n",
      "        - Which inhibitors, antagonists, agonists, negative allosteric modulators (NAM), positive allosteric modulators (PAM) are required for target modulation in the given disease? \n",
      "    - Which patients would respond the therapy?\n",
      "    - Is the proposed mode of action on the target desirable and commercially viable in a clinical setting?\n",
      "    - What are advantages and disadvantages of different therapeutic modalities (antibodies, small molecules, antisense oligonucleotides, PROTACs, molecular glue, peptide macrocycles, and so on) for tackling the target?\n",
      "\n",
      "    - Alternative indications:\n",
      "    - Describe alternative indication for modulators of the target and explain why.\n",
      "\n",
      "    Task 2: Develop a target assessment strategy for Integrase in HIV 1 infection in maximal 500 words.\n",
      "\n",
      "    Outline a 1-year Target Assessment (TA) to Lead Identification (LI) plan. Describe High Level TA-LI plans.\n",
      "    - Make an emphasis on key inflection points that will inform the feasibility of the project. \n",
      "    - Address status of in-vitro platforms, translational in vivo models (mechanistic models, not necessarily so called 'disease models')\n",
      "    and describe what needs to be established. Elaborate on tractability and major challenges for advancement in a drug discovery portfolio.\n",
      "    - Discuss potential biomarkers and readouts for efficacy and target engagement.\n",
      "\n",
      "    Task 3: Safety assessment\n",
      "    - Does the target show bias towards expression in the desired organ (e.g. CNS)?\n",
      "    - Is it specifically expressed in the organ (e.g. brain)?\n",
      "    - Are there disease specific expression databases?\n",
      "    - Are there tissue-selective isoforms of the target?\n",
      "    - Are there condition-specific isoforms of the target?\n",
      "    - What regulates the alternative splicing that makes one isoform versus the other?\n",
      "    - How large is the expression of the target in the mouse model intended for in vivo tests?\n",
      "    - Is major phenotype reported in target knockouts and/or expression of rodent models?\n",
      "    - Are there published differences in expression between human and rodent models.\n",
      "    - What are the species differences that could be used to interpret rodent safety data on the target?\n",
      "    - What are the peripherial safety risks (oncogensis)?\n",
      "    - Can the modulation of the target promote tumor formation?\n",
      "    - Is there a way to assess on-target safety concerns?\n",
      "    - What are the safety concerns in case of exaggerated pharmacology?\n",
      "    - Will it disrupt cellular functions (e.g. endosomes, lysosomes, nuclear, mitochondrial) function with all its safety liability?\n",
      "    - How large is the risk for immunogenicity (related to biologics/antibody based approaches)?\n",
      "    - If the target is an enzyme, do polymorphisms in the human gene alter the protein enzyme activity?\n",
      "\n",
      "    Provide the corresponding literature references in the format (First author, Journal, Year, Volume, Issue, Pages, DOI). If any are missing or not available, please mark as N/A.\n",
      "\n",
      "    Let's work this out in a step by step way to be sure we have the right answer.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "You are an expert in drug discovery and clinical target rationale. Your role is to develop a comprehensive scientific rationale for the given target in the specified disease. You will:\n",
      "                    Formulate a working hypothesis based on the provided information.\n",
      "                    Analyze the clinical target rationale, focusing on human biology evidence.\n",
      "                    Evaluate the relevance of the target to the disease and its physiological processes.\n",
      "                    Assess genetic links, phenotypes, and clinical evidence related to the target.\n",
      "                    Identify challenges in the drug discovery program for this target.\n",
      "                    Suggest alternative indications for target modulators.\n",
      "                    Use the use_pubmed_api function to find and cite relevant scientific literature.\n",
      "                    Ensure your response covers all points requested in the prompt, with a minimum of 2000 words for the main rationale.\n",
      "\n",
      "\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: Moderator\n",
      "\u001b[0m\n",
      "\u001b[31m\n",
      ">>>>>>>> USING AUTO REPLY...\u001b[0m\n",
      "\u001b[33mModerator\u001b[0m (to chat_manager):\n",
      "\n",
      "Thank you for the overview and the delineated tasks. Each task will be assigned to the corresponding agent to ensure a focused and efficient approach to developing a comprehensive drug discovery strategy. \n",
      "\n",
      "For Task 1:\n",
      "SAR, you are tasked to develop a detailed scientific rationale for using Integrase as a target in HIV-1 infection treatment. Please cover all the listed subtasks in your analysis. Use the use_pubmed_api function to support your arguments with relevant scientific literature.\n",
      "\n",
      "For Task 2:\n",
      "TAG, your assignment is to develop a concise yet comprehensive Target Assessment to Lead Identification (TA-LI) plan for Integrase in the context of HIV-1 infection, adhering to the 500-word limit. Please outline key milestones, challenges, potential biomarkers, and the readiness of translational models. Utilize the use_pubhelp_api function to reference current literature.\n",
      "\n",
      "For Task 3:\n",
      "SAFEA, you are responsible for performing a thorough safety assessment for the target Integrase considering its usage in the context of drug development for HIV-1 infection. Address all the specified safety concerns, expression patterns, and species differences in your analysis.\n",
      "\n",
      "As a Moderator, I will ensure all discussions are well-synchronized and the final report will be compiled efficiently with accurate referencing and adherence to prompt requirements. Let's commence with the tasks, please proceed, SAR.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: SAR\n",
      "\u001b[0m\n",
      "\u001b[33mSAR\u001b[0m (to chat_manager):\n",
      "\n",
      "### Working Hypothesis\n",
      "\n",
      "The primary hypothesis for targeting HIV-1 integrase in the treatment of HIV-1 infection with a new inhibitor is based on several key assumptions and aims. The goal is to develop a compound that is more potent and offers a higher barrier to resistance compared to existing integrase inhibitors like dolutegravir. Specifically, the new hypothetical integrase inhibitor would need to interact with the integrase enzyme in a manner that not only prevents the integration of viral DNA into the host genome but also addresses issues of viral resistance that can emerge with current therapies. This new compound should ideally be compatible for use in combination therapy, meet a significant unmet medical need, offer improved patient compliance, and present fewer side effects.\n",
      "\n",
      "#### Propositions:\n",
      "1. **Unmet Medical Need**: Despite the effectiveness of existing treatments including dolutegravir, resistance to HIV drugs remains a significant barrier. There is also a need for treatments that have less stringent requirements on adherence to remain effective, thereby increasing patient compliance and overall quality of life.\n",
      "   \n",
      "2. **Combination Therapy**: Given the complexity of HIV therapy, which often requires lifelong adherence to a therapeutic regimen, the new integrase inhibitor should be evaluated for its compatibility and synergistic potential with other antiretroviral agents.\n",
      "\n",
      "3. **Predictive Biomarkers**: Developing biomarkers that can predict the efficacy of the new inhibitor will be crucial. Currently, the most relevant biomarkers involve measurements of viral load and CD4+ cell counts; however, novel biomarkers might include genetic variants of the virus that confer resistance to existing treatments.\n",
      "\n",
      "### Clinical Target Rationale\n",
      "\n",
      "#### Target Relevance to Disease Biology\n",
      "HIV-1 integrase is essential for the replication of the virus, as it facilitates the integration of the viral DNA into the host's genome, a critical step in the viral lifecycle. Therefore, inhibiting this enzyme directly impacts the virus's ability to replicate and persist in the host.\n",
      "\n",
      "#### Target Expression and Physiological Relevance\n",
      "Integrase is expressed by the HIV-1 virus and not by the host, making it an ideal target due to the lack of homologous proteins in humans, which reduces potential off-target effects.\n",
      "\n",
      "#### Phenotypes and Genotypes\n",
      "Mutations in the integrase gene that confer resistance to current integrase inhibitors highlight the dynamic nature of this enzymatic target and justify the development of new inhibitors that can overcome these resistance profiles.\n",
      "\n",
      "#### Genetic Link and Clinical Evidence\n",
      "The development of resistance to first-generation integrase inhibitors through mutations in the integrase gene itself provides a clear genetic link between the target and the disease. Clinical failure due to resistance has been documented, providing direct evidence of the target's role.\n",
      "\n",
      "#### Modulation Requirement\n",
      "The primary requirement for modulating this target is the inhibition of the integrase enzyme's ability to insert viral DNA into the host genome, thereby preventing viral replication.\n",
      "\n",
      "### Challenges for the Drug Discovery Program\n",
      "Developing a new integrase inhibitor that is more potent and has a higher resistance barrier than dolutegravir involves addressing several challenges:\n",
      "- **Resistance Mechanisms**: Understanding the structural mechanisms by which the virus develops resistance to integrase inhibitors is crucial.\n",
      "- **Pharmacokinetics/Pharmacodynamics (PK/PD)**: Developing compounds with optimal PK/PD profiles that can be taken less frequently than current therapies.\n",
      "- **Safety Profile**: Ensuring the new inhibitor does not induce unacceptable side effects.\n",
      "- **IDA Strategy**: Investigating whether a structure-based drug design (information driven approach) could lead to the discovery of novel inhibitors that avoid known resistance mechanisms.\n",
      "\n",
      "#### RNA interference (RNAi) and small molecules\n",
      "Exploring other modes of action such as RNA interference (RNAi) could offer alternative ways to inhibit integrase expression. Small molecule inhibitors are the most extensively developed and studied, but peptide macrocycles, molecular glues, and PROTACs represent innovative approaches that could potentially address resistance issues.\n",
      "\n",
      "### Alternative Indications\n",
      "Should the novel integrase inhibitors demonstrate unique properties, they could potentially be investigated for other retroviral infections where integrase plays a role, albeit detailed virological studies would be necessary to establish this potential.\n",
      "\n",
      "The next step is to corroborate these points with relevant scientific literature using the use_pubmed_api function to ensure the accuracy and recency of the data supporting the target rationale for Integrase in HIV-1 infection. Let's proceed to gather the relevant literature next.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: SAFEA\n",
      "\u001b[0m\n",
      "\u001b[33mSAFEA\u001b[0m (to chat_manager):\n",
      "\n",
      "\u001b[32m***** Suggested tool call (call_YspX38CNpD0yTImS74kryRXv): use_pubmed_api *****\u001b[0m\n",
      "Arguments: \n",
      "{\"query\": \"HIV integrase inhibitors resistance\"}\n",
      "\u001b[32m*******************************************************************************\u001b[0m\n",
      "\u001b[32m***** Suggested tool call (call_fv8qsMV9oe1jYI1gcH5aPI8e): use_pubmed_api *****\u001b[0m\n",
      "Arguments: \n",
      "{\"query\": \"Clinical impact of new HIV integrase inhibitors\"}\n",
      "\u001b[32m*******************************************************************************\u001b[0m\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: TAG\n",
      "\u001b[0m\n",
      "\u001b[35m\n",
      ">>>>>>>> EXECUTING FUNCTION use_pubmed_api...\u001b[0m\n",
      "PubMed API called with query: HIV integrase inhibitors resistance, max_results: 10\n",
      "PubMedAPI.query called with: HIV integrase inhibitors resistance, 10\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[runtime logging] log_function_use: autogen logger is None\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Retrieved 10 papers from PubMed\n",
      "PubMed API call completed\n",
      "\u001b[35m\n",
      ">>>>>>>> EXECUTING FUNCTION use_pubmed_api...\u001b[0m\n",
      "PubMed API called with query: Clinical impact of new HIV integrase inhibitors, max_results: 10\n",
      "PubMedAPI.query called with: Clinical impact of new HIV integrase inhibitors, 10\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[runtime logging] log_function_use: autogen logger is None\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Retrieved 10 papers from PubMed\n",
      "PubMed API call completed\n",
      "\u001b[33mTAG\u001b[0m (to chat_manager):\n",
      "\n",
      "\u001b[33mTAG\u001b[0m (to chat_manager):\n",
      "\n",
      "\u001b[32m***** Response from calling tool (call_YspX38CNpD0yTImS74kryRXv) *****\u001b[0m\n",
      "Title: Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV/AIDS Center in NE Romania.\n",
      "Authors: Loghin II, Rusu ȘA, Vâţă A, Cobaschi M, Cecan I, Manciuc C, Dorobăţ CM\n",
      "Journal: Medicina (Kaunas, Lithuania), 2024\n",
      "DOI: 10.3390/medicina60060854\n",
      "Abstract: <i>Background and Objectives</i>: Antiretroviral therapy (ART) has revolutionized the management of HIV infection, transforming it from a once-debilitating disease to a chronic, manageable condition. ...\n",
      "\n",
      "Title: High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.\n",
      "Authors: Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E\n",
      "Journal: PloS one, 2024\n",
      "DOI: 10.1371/journal.pone.0305129\n",
      "Abstract: In 2019, WHO recommended dolutegravir (DTG) as a backbone for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). According to the 2018 Uganda's HIV treatm...\n",
      "\n",
      "Title: Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1.\n",
      "Authors: Giammarino F, Sönnerborg A, Ceña-Diez R\n",
      "Journal: Frontiers in cellular and infection microbiology, 2024\n",
      "DOI: 10.3389/fcimb.2024.1334126\n",
      "Abstract: The naturally occurring dipeptide Tryptophylglycine (WG) is enhanced in human immunodeficiency virus (HIV-1) infected Elite Controllers (EC). We have shown that this dipeptide has an anti-HIV-1 effect...\n",
      "\n",
      "Title: A review of dolutegravir-associated weight gain and secondary metabolic comorbidities.\n",
      "Authors: Jemal M\n",
      "Journal: SAGE open medicine, 2024\n",
      "DOI: 10.1177/20503121241260613\n",
      "Abstract: Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations. Excess...\n",
      "\n",
      "Title: HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.\n",
      "Authors: Capeau J, Lagathu C, Ngono Ayissi K, Fève B, Béréziat V\n",
      "Journal: Annales d'endocrinologie, 2024\n",
      "DOI: 10.1016/j.ando.2024.05.005\n",
      "Abstract: HIV infection has been controlled only since the introduction of triple therapy in 1996, combining, as antiretroviral agents, two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease i...\n",
      "\n",
      "Title: Clinical considerations when switching antiretroviral therapy.\n",
      "Authors: Fernández A, Imaz A\n",
      "Journal: Expert review of clinical pharmacology, 2024\n",
      "DOI: 10.1080/17512433.2024.2365826\n",
      "Abstract: Antiretroviral therapy (ART) can be personalized through simple formulations with high resistance barriers, favorable safety profiles, and novel administration routes. Switching treatments has become ...\n",
      "\n",
      "Title: Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.\n",
      "Authors: West RE, Oberly PJ, Saylor AJ, Riddler SA, Nolin TD, Devanathan AS\n",
      "Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024\n",
      "DOI: 10.1016/j.jchromb.2024.124164\n",
      "Abstract: Although antiretroviral therapy (ART) is highly effective for the treatment of HIV-1 infection to suppress virus in the blood, HIV persists in tissues. HIV persistence in the tissues is due to numerou...\n",
      "\n",
      "Title: Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.\n",
      "Authors: Karabay O\n",
      "Journal: AIDS (London, England), 2024\n",
      "DOI: 10.1097/QAD.0000000000003885\n",
      "Abstract: No abstract available...\n",
      "\n",
      "Title: <i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.\n",
      "Authors: Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C, Lermechain F, Plantier J-C, Alessandri-Gradt E\n",
      "Journal: Microbiology spectrum, 2024\n",
      "DOI: 10.1128/spectrum.03895-23\n",
      "Abstract: The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical...\n",
      "\n",
      "Title: Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.\n",
      "Authors: Dekker JG, Klaver B, Berkhout B, Das AT\n",
      "Journal: Journal of virology, 2024\n",
      "DOI: 10.1128/jvi.00335-24\n",
      "Abstract: No abstract available...\n",
      "\u001b[32m**********************************************************************\u001b[0m\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[33mTAG\u001b[0m (to chat_manager):\n",
      "\n",
      "\u001b[32m***** Response from calling tool (call_fv8qsMV9oe1jYI1gcH5aPI8e) *****\u001b[0m\n",
      "Title: Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.\n",
      "Authors: Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, Crusells-Canales M, Sierra JO, DeMoor R, Scherzer J, Ait-Khaled M, Bontempo G, Gill M, Patel N, D'Amico R, Hove K, Baugh B, Barnes N, Hadi M, Low EL, Anand SB, Hamilton A, Garges HP, Czarnogorski M\n",
      "Journal: Journal of the International AIDS Society, 2024\n",
      "DOI: 10.1002/jia2.26243\n",
      "Abstract: Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long-acting (LA) regimen recommended for maintaining HIV-1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in...\n",
      "\n",
      "Title: Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.\n",
      "Authors: Fletcher L, Burrowes S, Sabin LL, McCann N, Khan GK, Ruiz-Mercado G, Johnson S, Kimmel SD, Pierre C, Drainoni ML\n",
      "Journal: AIDS patient care and STDs, 2024\n",
      "DOI: 10.1089/apc.2024.0048\n",
      "Abstract: Long-acting injectable (LAI) antiretroviral therapy (ART) has the potential to change the lives of people living with HIV (PLWH). To ensure equitable access to new treatment modalities, we examined th...\n",
      "\n",
      "Title: Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.\n",
      "Authors: Wohlfeiler MB, Brunet L, Cochran Q, Fusco JS, Hsu RK, Fusco GP\n",
      "Journal: Journal of the International Association of Providers of AIDS Care, 2024\n",
      "DOI: 10.1177/23259582241245223\n",
      "Abstract: We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB + RPV LAI) monthly injections schedule....\n",
      "\n",
      "Title: Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture.\n",
      "Authors: McMullan HM, Gansemer BM, Thayer SA\n",
      "Journal: Frontiers in pharmacology, 2024\n",
      "DOI: 10.3389/fphar.2024.1369757\n",
      "Abstract: <b>Introduction:</b> Antiretroviral (ARV) drugs have improved prognoses for people living with HIV. However, HIV-associated neurocognitive disorders (HAND) persist despite undetectable viral loads. So...\n",
      "\n",
      "Title: Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.\n",
      "Authors: Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A, Unknown\n",
      "Journal: BMJ open, 2024\n",
      "DOI: 10.1136/bmjopen-2023-080606\n",
      "Abstract: The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). K...\n",
      "\n",
      "Title: Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.\n",
      "Authors: Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R, Unknown\n",
      "Journal: Clinical pharmacokinetics, 2023\n",
      "DOI: 10.1007/s40262-023-01289-5\n",
      "Abstract: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to ...\n",
      "\n",
      "Title: Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.\n",
      "Authors: Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, Günthard HF, Zangerle R, Smith C, Castagna A, d'Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, Fontas E, González E, Wasmuth JC, Sönnerborg A, De Wit S, Chkhartishvili N, Stephan C, Petoumenos K, Jaschinski N, Vannappagari V, Gallant J, Young L, Volny Anne A, Greenberg L, Martín-Iguacel R, Poveda E, Llibre JM, Unknown\n",
      "Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023\n",
      "DOI: 10.1093/cid/ciad219\n",
      "Abstract: There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluat...\n",
      "\n",
      "Title: Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.\n",
      "Authors: Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, McCauley M, Rinehart AR, St Clair M, Ford SL, Rooney JF, Adeyeye A, Chariyalertsak S, Mayer K, Arduino RC, Cohen MS, Grinsztejn B, Hanscom B, Landovitz RJ, Eshleman SH\n",
      "Journal: Antimicrobial agents and chemotherapy, 2023\n",
      "DOI: 10.1128/aac.00053-23\n",
      "Abstract: HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have s...\n",
      "\n",
      "Title: From Capillary Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using In Vitro Diagnostic (IVD) Assays and Software.\n",
      "Authors: Mohamed S, Boulmé R, Sayada C\n",
      "Journal: Viruses, 2023\n",
      "DOI: 10.3390/v15020571\n",
      "Abstract: Drug-resistance mutations were mostly detected using capillary electrophoresis sequencing, which does not detect minor variants with a frequency below 20%. Next-Generation Sequencing (NGS) can now det...\n",
      "\n",
      "Title: Cabotegravir Exposure of Zebrafish (<i>Danio rerio</i>) Embryos Impacts on Neurodevelopment and Behavior.\n",
      "Authors: Zizioli D, Zanella I, Mignani L, Degli Antoni M, Castelli F, Quiros-Roldan E\n",
      "Journal: International journal of molecular sciences, 2023\n",
      "DOI: 10.3390/ijms24031994\n",
      "Abstract: As most new medications, Cabotegravir (CAB) was recently approved as an antiretroviral treatment of HIV infection without in-depth safety information on in utero exposure. Although no developmental to...\n",
      "\u001b[32m**********************************************************************\u001b[0m\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: Initialiser\n",
      "\u001b[0m\n",
      "\u001b[31m\n",
      ">>>>>>>> USING AUTO REPLY...\u001b[0m\n",
      "\u001b[33mInitialiser\u001b[0m (to chat_manager):\n",
      "\n",
      "\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: Moderator\n",
      "\u001b[0m\n",
      "\u001b[31m\n",
      ">>>>>>>> USING AUTO REPLY...\u001b[0m\n",
      "\u001b[33mModerator\u001b[0m (to chat_manager):\n",
      "\n",
      "Thank you, SAR, for the detailed scientific rationale outline. The references provided by the use_pubmed_api function should efficiently bolster the arguments and data laid out in the rationale.\n",
      "\n",
      "Now, let's proceed with the next task. TAG, it's your turn to develop and outline the comprehensive 1-year Target Assessment to Lead Identification (TA-LI) plan for the drug target 'Integrase' in the context of HIV-1 infection. Please also utilize the use_pubmed_api function to enrich your report with relevant literature.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: SAR\n",
      "\u001b[0m\n",
      "\u001b[33mSAR\u001b[0m (to chat_manager):\n",
      "\n",
      "Thank you, Moderator. I will now proceed with outlining the 1-year Target Assessment to Lead Identification (TA-LI) plan for Integrase in HIV-1 infection.\n",
      "\n",
      "### Target Assessment to Lead Identification (TA-LI) Plan for Integrase\n",
      "\n",
      "**1. Initial Assessment and Rationale**\n",
      "   - **Inflection Points**: Immediate focus on assessing the existing and emergent resistance profiles against current integrase inhibitors, especially dolutegravir. This early assessment will guide the necessity and direction of novel inhibitor designs.\n",
      "   - **Unmet Needs**: Although existing integrase inhibitors are effective, issues like viral resistance and long-term side effects persist, presenting an unmet need for more efficacious and safer interventions.\n",
      "\n",
      "**2. Status of In-Vitro Platforms**\n",
      "   - Currently, several robust in vitro platforms are available for studying HIV integrase activity, including biochemical assays for enzyme inhibition and cellular assays using viral replication in host cells.\n",
      "   - **Actions Needed**: Enhancements are necessary in high-throughput screening platforms to quickly evaluate the potency of novel compounds against a broader range of viral genetic variants.\n",
      "\n",
      "**3. Translational In Vivo Models**\n",
      "   - **Current Models**: Mouse models engineered to produce human T cells (Hu-mouse models), allowing for an assessment of antiviral efficacy in a living system.\n",
      "   - **Development Needs**: There's a need to establish more sophisticated models that can mimic drug resistance mechanisms observed in humans more accurately.\n",
      "\n",
      "**4. Tractability and Drug Development Challenges**\n",
      "   - **Tractability**: HIV integrase is a proven druggable target with multiple approved inhibitors, confirming the feasibility of targeting this protein.\n",
      "   - **Challenges**: The major challenges include overcoming the drug resistance that evolves rapidly due o the high mutation rate of HIV and ensuring the brain penetration of the inhibitors to address HIV-associated neurocognitive disorders.\n",
      "\n",
      "**5. Biomarkers and Readouts**\n",
      "   - **Efficacy Biomarkers**: Viral load and integration site diversity can serve as direct biomarkers for evaluating the efficacy of integrase inhibitors.\n",
      "   - **Target Engagement**: Indicators of drug-target interaction and engagement would primarily include the reduction in the integration of viral DNA into the host genome, which can be quantified using novel genomic techniques.\n",
      "\n",
      "**6. Commercial Viability**\n",
      "   - Given the ongoing global burden of HIV, an effective integrase inhibitor would have significant commercial potential, particularly if it can offer advantages over existing therapies in terms of efficacy, safety, resistance management, or dosing convenience.\n",
      "\n",
      "**7. Milestones for the Next 1-Year**\n",
      "   - **Q1-Q2**: Complete a comprehensive literature review and gap analysis on existing knowledge about HIV integrase, focusing on resistance mechanisms.\n",
      "   - **Q3**: Establish partnerships for advanced genomic and proteomic studies to enhance understanding of integrase function and its interaction with inhibitors.\n",
      "   - **Q4**: Initiate proof-of-concept studies using lead compounds in advanced in vivo models.\n",
      "\n",
      "To support this plan, I will use the use_pubmed_api function to find relevant literature that provides recent advancements and existing gaps in the knowledge concerning HIV integrase inhibitors.\n",
      "\n",
      "**Requesting Literature Retrieval**\n",
      "I will now request the retrieval of relevant scientific literature to support this TA-LI plan further.\n",
      "\u001b[32m***** Suggested tool call (call_CQKpwlbsl6iKuUSRB5weUZF6): use_pubmed_api *****\u001b[0m\n",
      "Arguments: \n",
      "{\"query\":\"advancements in HIV integrase inhibitors\"}\n",
      "\u001b[32m*******************************************************************************\u001b[0m\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: SAFEA\n",
      "\u001b[0m\n",
      "\u001b[35m\n",
      ">>>>>>>> EXECUTING FUNCTION use_pubmed_api...\u001b[0m\n",
      "PubMed API called with query: advancements in HIV integrase inhibitors, max_results: 10\n",
      "PubMedAPI.query called with: advancements in HIV integrase inhibitors, 10\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[runtime logging] log_function_use: autogen logger is None\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Retrieved 10 papers from PubMed\n",
      "PubMed API call completed\n",
      "\u001b[33mSAFEA\u001b[0m (to chat_manager):\n",
      "\n",
      "\u001b[33mSAFEA\u001b[0m (to chat_manager):\n",
      "\n",
      "\u001b[32m***** Response from calling tool (call_CQKpwlbsl6iKuUSRB5weUZF6) *****\u001b[0m\n",
      "Title: Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.\n",
      "Authors: Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF\n",
      "Journal: Journal of the International AIDS Society, 2024\n",
      "DOI: 10.1002/jia2.26268\n",
      "Abstract: Recent evidence has raised questions about whether newer HIV treatment regimens, including dolutegravir (DTG) and tenofovir alafenamide (TAF), are associated with increases in blood pressure (BP)....\n",
      "\n",
      "Title: Advances in HIV Management During Pregnancy and Infant Feeding.\n",
      "Authors: Espinal M, Yee LM, Fisher SA\n",
      "Journal: Infectious disease clinics of North America, 2024\n",
      "DOI: 10.1016/j.idc.2024.06.005\n",
      "Abstract: Recent advances in human immunodeficiency virus (HIV) management during pregnancy and infant feeding encompass several key elements: expanded HIV testing guidance; growing evidence of safety, efficacy...\n",
      "\n",
      "Title: Brief Histories of Retroviral Integration Research and Associated International Conferences.\n",
      "Authors: Grandgenett DP, Engelman AN\n",
      "Journal: Viruses, 2024\n",
      "DOI: 10.3390/v16040604\n",
      "Abstract: The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes. Beca...\n",
      "\n",
      "Title: D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.\n",
      "Authors: Turkova A, Chan MK, Kityo C, Kekitiinwa AR, Musoke P, Violari A, Variava E, Archary M, Cressey TR, Chalermpantmetagul S, Sawasdichai K, Ounchanum P, Kanjanavanit S, Srirojana S, Srirompotong U, Welch S, Bamford A, Epalza C, Fortuny C, Colbers A, Nastouli E, Walker S, Carr D, Conway M, Spyer MJ, Parkar N, White I, Nardone A, Thomason MJ, Ferrand RA, Giaquinto C, Ford D, Unknown\n",
      "Journal: Contemporary clinical trials, 2024\n",
      "DOI: 10.1016/j.cct.2024.107540\n",
      "Abstract: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of DTG/3TC in...\n",
      "\n",
      "Title: Analysis of antiretroviral therapy interruption in people living with HIV during the 2010-2021 Period.\n",
      "Authors: Contreras-Macías E, Gutiérrez-Pizarraya A, Pineda-Vergara JA, Morillo-Verdugo R\n",
      "Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2024\n",
      "DOI: 10.1016/j.farma.2024.03.007\n",
      "Abstract: In the context of the advancement of antiretroviral therapy and, as the characteristics of people living with HIV progress toward an aging population, understanding the causes of treatment interruptio...\n",
      "\n",
      "Title: <i>Chicoric acid</i> advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway.\n",
      "Authors: Zhang W, Liu Y, Zhou J, Qiu T, Xie H, Pu Z\n",
      "Journal: Clinical and experimental hypertension (New York, N.Y. : 1993), 2024\n",
      "DOI: 10.1080/10641963.2024.2326021\n",
      "Abstract: This study aimed to examine the impact of CA on DN and elucidate its underlying molecular mechanisms of inflammation....\n",
      "\n",
      "Title: Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review.\n",
      "Authors: Azzman N, Gill MSA, Hassan SS, Christ F, Debyser Z, Mohamed WAS, Ahemad N\n",
      "Journal: Reviews in medical virology, 2024\n",
      "DOI: 10.1002/rmv.2529\n",
      "Abstract: The discovery of anti-retroviral (ARV) drugs over the past 36 years has introduced various classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcripta...\n",
      "\n",
      "Title: Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study.\n",
      "Authors: Brites C, Lacerda M, Sprinz E, Bay M, Pinto G, Azevedo P, Luz E, Lins-Kusterer L, Netto EM\n",
      "Journal: Frontiers in medicine, 2024\n",
      "DOI: 10.3389/fmed.2024.1302710\n",
      "Abstract: Currently, integrase inhibitors (INIs)-based ART regimens are the preferred initial therapy for AIDS patients. There is scarce information on the use of dolutegravir (DTG) among late-presenter people ...\n",
      "\n",
      "Title: Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV.\n",
      "Authors: Fisher SA, Madden N, Espinal M, Garcia PM, Jao JK, Yee LM\n",
      "Journal: Clinical obstetrics and gynecology, 2024\n",
      "DOI: 10.1097/GRF.0000000000000860\n",
      "Abstract: Over the last 4 decades, significant advances in the care of HIV during pregnancy have successfully reduced, and nearly eliminated, the risk of perinatal HIV transmission. The baseline risk of transmi...\n",
      "\n",
      "Title: Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors.\n",
      "Authors: Hikichi Y, Grover JR, Schäfer A, Mothes W, Freed EO\n",
      "Journal: Science advances, 2024\n",
      "DOI: 10.1126/sciadv.adn0042\n",
      "Abstract: People living with human immunodeficiency virus (HIV) receiving integrase strand transfer inhibitors (INSTIs) have been reported to experience virological failure in the absence of resistance mutation...\n",
      "\u001b[32m**********************************************************************\u001b[0m\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: TAG\n",
      "\u001b[0m\n",
      "\u001b[33mTAG\u001b[0m (to chat_manager):\n",
      "\n",
      "Thank you, TAG, for the comprehensive outline of the 1-year Target Assessment to Lead Identification (TA-LI) plan for Integrase in HIV-1 infection. The details you've provided, especially on milestones, key biomarkers, and global challenges, align well with the thorough strategy required for successful drug development.\n",
      "\n",
      "With this TA-LI plan enriched by relevant data from the recent literature, including the advancements in HIV integrase inhibitors, we have an informed basis to proceed effectively.\n",
      "\n",
      "Finally, it's SAFEA's turn to perform the safety assessment for Integrase as a target in our drug discovery strategy. SAFEA, please assess the safety profile of targeting Integrase, taking into account tissue specificity, expression patterns, potential safety risks including immunogenicity, and any evidence of species differences that may influence translational models. Please utilize any required tools or data sources to substantiate your findings effectively.\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: Initialiser\n",
      "\u001b[0m\n",
      "\u001b[31m\n",
      ">>>>>>>> USING AUTO REPLY...\u001b[0m\n",
      "\u001b[33mInitialiser\u001b[0m (to chat_manager):\n",
      "\n",
      "\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\u001b[32m\n",
      "Next speaker: Moderator\n",
      "\u001b[0m\n",
      "\u001b[31m\n",
      ">>>>>>>> USING AUTO REPLY...\u001b[0m\n",
      "\u001b[33mModerator\u001b[0m (to chat_manager):\n",
      "\n",
      "As the Moderator, it seems there was an oversight, and no specifics have been provided for the agents to proceed with their assigned tasks, particularly for SAFEA's task on the safety assessment for Integrase.\n",
      "\n",
      "Now, SAFEA, please conduct a thorough safety assessment of the proposed drug target Integrase, covering all aspects outlined earlier. This should include:\n",
      "- Expression patterns and tissue specificity.\n",
      "- Potential species differences impacting translational models.\n",
      "- On-target and off-target safety concerns.\n",
      "- Risks associated with exaggerated pharmacology, such as potential immunogenicity concerns.\n",
      "- The potential for modulation of the target to promote tumor formation or other serious side effects.\n",
      "\n",
      "Please ensure to reference any relevant literature and data to support your safety profile conclusions. If necessary, use appropriate functions like use_pubmed_api to retrieve the most up-to-date and relevant information. Proceed when ready, SAFEA.\n",
      "\n",
      "--------------------------------------------------------------------------------\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "ChatResult(chat_id=None, chat_history=[{'content': \"You are a AI assistant with a background in drug discovery.\\n\\n    Given target: Integrase\\n    Given disease: HIV 1 infection\\n    Given mode of action: Dolutegravir is an HIV-1 antiviral agent. It inhibits HIV integrase by binding to the active site and blocking the strand transfer step of retroviral DNA integration in the host cell. The strand transfer step is essential in the HIV replication cycle and results in the inhibition of viral activity. Dolutegravir has a mean EC50 value of 0.5 nM (0.21 ng/mL) to 2.1 nM (0.85 ng/mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells.4\\n\\n    Context:\\n    The current treatment for HIV-1 infection involves a combination of antiretroviral drugs to suppress viral replication and prevent the progression of the disease. Dolutegravir is a potent integrase inhibitor that has shown high efficacy in the treatment of HIV-1 infection. However, there is a need to develop a scientific rationale for the use of dolutegravir in the treatment of HIV-1 infection, highlighting the working hypothesis, clinical target rationale, and challenges for the drug discovery program related to the target.\\n\\n    Task 1: Develop a scientific rationale for Integrase in HIV 1 infection.\\n\\n    Highlight the working hypothesis for the clinical target rationale and human biology evidence by minimum 2000 words.\\n\\n    Describe as much as possible the evidence in humans or in human tissue that link the target, target space or approach to the pathogenesis of interest.\\n    If known, also describe here the wanted mode of action with regards to desired clinical outcome.\\n    Please avoid including only pre-clinical data in this section.\\n\\n    Use the following structure and provide a detailed description for each point:\\n    - Working hypothesis:\\n    - Create a detailed description of the following idea: Creating a new inhibitor for HIV-1 integrase that is more potent and has a higher barrier to resistance than dolutegravir.\\n    - Is there are significant unmet medical need?\\n    - Is it suitable for combination therapy?\\n    - Which predictive biomarkers exist for the target related to the disease?\\n        - Provide a detailed description of existing clinical relevant biomarkers.\\n\\n    - Clinical target rationale:\\n    - How relevant is the target location to the disease biology?\\n    - How it the target expression altered in human disease?\\n    - How is the target involved in the physiological process relevant to the disease?\\n    - Which phenotypes and genotypes were identified for the target?\\n    - How is the genetic link between the target and the disease?\\n    - Describe the evidence provided in clinics or by tools acting on the pathway where the target is involved.\\n    - Which kind of target modulation is required to treat the disease?\\n\\n    - Challenges for the drug discovery program related to the target.\\n    - Check the following idea for details on small molecule compounds: Creating a new inhibitor for HIV-1 integrase that is more potent and has a higher barrier to resistance than dolutegravir..\\n    - Is a 'information driven approach' (IDA) strategy based on available small molecules possible?\\n        - Which small molecular modulators of the target known?\\n        - Which inhibitors, antagonists, agonists, negative allosteric modulators (NAM), positive allosteric modulators (PAM) are required for target modulation in the given disease? \\n    - Which patients would respond the therapy?\\n    - Is the proposed mode of action on the target desirable and commercially viable in a clinical setting?\\n    - What are advantages and disadvantages of different therapeutic modalities (antibodies, small molecules, antisense oligonucleotides, PROTACs, molecular glue, peptide macrocycles, and so on) for tackling the target?\\n\\n    - Alternative indications:\\n    - Describe alternative indication for modulators of the target and explain why.\\n\\n    Task 2: Develop a target assessment strategy for Integrase in HIV 1 infection in maximal 500 words.\\n\\n    Outline a 1-year Target Assessment (TA) to Lead Identification (LI) plan. Describe High Level TA-LI plans.\\n    - Make an emphasis on key inflection points that will inform the feasibility of the project. \\n    - Address status of in-vitro platforms, translational in vivo models (mechanistic models, not necessarily so called 'disease models')\\n    and describe what needs to be established. Elaborate on tractability and major challenges for advancement in a drug discovery portfolio.\\n    - Discuss potential biomarkers and readouts for efficacy and target engagement.\\n\\n    Task 3: Safety assessment\\n    - Does the target show bias towards expression in the desired organ (e.g. CNS)?\\n    - Is it specifically expressed in the organ (e.g. brain)?\\n    - Are there disease specific expression databases?\\n    - Are there tissue-selective isoforms of the target?\\n    - Are there condition-specific isoforms of the target?\\n    - What regulates the alternative splicing that makes one isoform versus the other?\\n    - How large is the expression of the target in the mouse model intended for in vivo tests?\\n    - Is major phenotype reported in target knockouts and/or expression of rodent models?\\n    - Are there published differences in expression between human and rodent models.\\n    - What are the species differences that could be used to interpret rodent safety data on the target?\\n    - What are the peripherial safety risks (oncogensis)?\\n    - Can the modulation of the target promote tumor formation?\\n    - Is there a way to assess on-target safety concerns?\\n    - What are the safety concerns in case of exaggerated pharmacology?\\n    - Will it disrupt cellular functions (e.g. endosomes, lysosomes, nuclear, mitochondrial) function with all its safety liability?\\n    - How large is the risk for immunogenicity (related to biologics/antibody based approaches)?\\n    - If the target is an enzyme, do polymorphisms in the human gene alter the protein enzyme activity?\\n\\n    Provide the corresponding literature references in the format (First author, Journal, Year, Volume, Issue, Pages, DOI). If any are missing or not available, please mark as N/A.\\n\\n    Let's work this out in a step by step way to be sure we have the right answer.\\n\\n\\n\\n\\n\\nYou are an expert in drug discovery and clinical target rationale. Your role is to develop a comprehensive scientific rationale for the given target in the specified disease. You will:\\n                    Formulate a working hypothesis based on the provided information.\\n                    Analyze the clinical target rationale, focusing on human biology evidence.\\n                    Evaluate the relevance of the target to the disease and its physiological processes.\\n                    Assess genetic links, phenotypes, and clinical evidence related to the target.\\n                    Identify challenges in the drug discovery program for this target.\\n                    Suggest alternative indications for target modulators.\\n                    Use the use_pubmed_api function to find and cite relevant scientific literature.\\n                    Ensure your response covers all points requested in the prompt, with a minimum of 2000 words for the main rationale.\\n\\n\", 'role': 'assistant'}, {'content': \"Hello everyone. We have assembled a great team today to answer questions and solve tasks. In attendance are:\\n\\nInitialiser: A user that can run Python code or input command line commands at a Linux terminal and report back the execution results.\\nModerator: You are 'Moderator', overseeing the drug discovery process. \\n                    ensure all aspects of the prompt are addressed, and synthesize a comprehensive final report. You will:\\n                    Your role is to coordinate the discussion between specialized agents,  ensuring all aspects of the prompt are addressed.\\n\\n                    1. Analyze the given prompt and break it down into subtasks for each agent.\\n                    2. Assign tasks to appropriate agents and manage their interactions.\\n                    3. Ensure all required sections (scientific rationale, target assessment strategy, and safety assessment) are thoroughly covered.\\n                    4. Compile and summarize the inputs from all agents into a cohesive final report.\\n                    5. Ensure all claims are properly referenced and the report follows the specified format.\\n                    6. Present the final output, including a complete list of references.\\nSAR: You are 'SAR', an expert in target discovery and clinical target rationale. Your role is to develop a comprehensive scientific rationale for the given target in the specified disease. \\n\\n    \\n    You will:\\n                    Formulate a working hypothesis based on the provided information.\\n                    Analyze the clinical target rationale, focusing on human biology evidence.\\n                    Evaluate the relevance of the target to the disease and its physiological processes.\\n                    Assess genetic links, phenotypes, and clinical evidence related to the target.\\n                    Identify challenges in the drug discovery program for this target.\\n                    Suggest alternative indications for target modulators.\\n                    Use the use_pubmed_api function TWICE to find and cite relevant scientific literature.\\n                    Ensure your response covers all points requested in the prompt, with a minimum of 2000 words for the main rationale.\\nSAFEA: You are 'SAFEA' an expert in safety when it comes to target discovery. Your role is to conduct a thorough safety assessment of the proposed drug target. You will:\\n\\n                    Evaluate target expression patterns and tissue specificity.\\n                    Analyze potential species differences between humans and animal models.\\n                    Assess on-target and off-target safety concerns, including peripheral risks.\\n                    Evaluate the risk of exaggerated pharmacology and immunogenicity.\\n                    Consider the impact of genetic polymorphisms on target function.\\n                    Provide a comprehensive safety profile addressing all points in the prompt's safety assessment section\\nTAG: You are 'TAG' a specialist in assessing targets for drug discovery. Your role is to develop and outline a comprehensive 1-year Target Assessment (TA) to Lead Identification (LI) plan for the proposed drug target. Your responsibilities include:\\n\\n                    Analyze and highlight key inflection points that will inform the project's feasibility.\\n                    Assess the status of in-vitro platforms and translational in vivo models.\\n                    Identify and describe what needs to be established in terms of platforms and models.\\n                    Elaborate on the target's tractability and major challenges for advancement in a drug discovery portfolio.\\n                    Discuss and propose potential biomarkers and readouts for efficacy and target engagement.\\n                    Outline a high-level TA-LI plan, focusing on critical milestones and decision points.\\n                    Evaluate the commercial viability and desirability of the proposed mode of action on the target in a clinical setting.\\n                    Assess the advantages and disadvantages of different therapeutic modalities for tackling the target.\\n                    Use the use_pubmed_api function to find relevant target assessment data and literature.\\n                    Provide a concise yet comprehensive target assessment strategy addressing all points in the prompt's target assessment section, within a 500-word limit.\\n\\n                    Your assessment should be evidence-based, drawing from the latest research and industry best practices in target assessment. \\n                    \\n                    Be prepared to interact with other specialists to ensure a well-rounded evaluation of the target\", 'role': 'user'}, {'content': \"Thank you for the overview and the delineated tasks. Each task will be assigned to the corresponding agent to ensure a focused and efficient approach to developing a comprehensive drug discovery strategy. \\n\\nFor Task 1:\\nSAR, you are tasked to develop a detailed scientific rationale for using Integrase as a target in HIV-1 infection treatment. Please cover all the listed subtasks in your analysis. Use the use_pubmed_api function to support your arguments with relevant scientific literature.\\n\\nFor Task 2:\\nTAG, your assignment is to develop a concise yet comprehensive Target Assessment to Lead Identification (TA-LI) plan for Integrase in the context of HIV-1 infection, adhering to the 500-word limit. Please outline key milestones, challenges, potential biomarkers, and the readiness of translational models. Utilize the use_pubhelp_api function to reference current literature.\\n\\nFor Task 3:\\nSAFEA, you are responsible for performing a thorough safety assessment for the target Integrase considering its usage in the context of drug development for HIV-1 infection. Address all the specified safety concerns, expression patterns, and species differences in your analysis.\\n\\nAs a Moderator, I will ensure all discussions are well-synchronized and the final report will be compiled efficiently with accurate referencing and adherence to prompt requirements. Let's commence with the tasks, please proceed, SAR.\", 'name': 'Moderator', 'role': 'user'}, {'content': \"### Working Hypothesis\\n\\nThe primary hypothesis for targeting HIV-1 integrase in the treatment of HIV-1 infection with a new inhibitor is based on several key assumptions and aims. The goal is to develop a compound that is more potent and offers a higher barrier to resistance compared to existing integrase inhibitors like dolutegravir. Specifically, the new hypothetical integrase inhibitor would need to interact with the integrase enzyme in a manner that not only prevents the integration of viral DNA into the host genome but also addresses issues of viral resistance that can emerge with current therapies. This new compound should ideally be compatible for use in combination therapy, meet a significant unmet medical need, offer improved patient compliance, and present fewer side effects.\\n\\n#### Propositions:\\n1. **Unmet Medical Need**: Despite the effectiveness of existing treatments including dolutegravir, resistance to HIV drugs remains a significant barrier. There is also a need for treatments that have less stringent requirements on adherence to remain effective, thereby increasing patient compliance and overall quality of life.\\n   \\n2. **Combination Therapy**: Given the complexity of HIV therapy, which often requires lifelong adherence to a therapeutic regimen, the new integrase inhibitor should be evaluated for its compatibility and synergistic potential with other antiretroviral agents.\\n\\n3. **Predictive Biomarkers**: Developing biomarkers that can predict the efficacy of the new inhibitor will be crucial. Currently, the most relevant biomarkers involve measurements of viral load and CD4+ cell counts; however, novel biomarkers might include genetic variants of the virus that confer resistance to existing treatments.\\n\\n### Clinical Target Rationale\\n\\n#### Target Relevance to Disease Biology\\nHIV-1 integrase is essential for the replication of the virus, as it facilitates the integration of the viral DNA into the host's genome, a critical step in the viral lifecycle. Therefore, inhibiting this enzyme directly impacts the virus's ability to replicate and persist in the host.\\n\\n#### Target Expression and Physiological Relevance\\nIntegrase is expressed by the HIV-1 virus and not by the host, making it an ideal target due to the lack of homologous proteins in humans, which reduces potential off-target effects.\\n\\n#### Phenotypes and Genotypes\\nMutations in the integrase gene that confer resistance to current integrase inhibitors highlight the dynamic nature of this enzymatic target and justify the development of new inhibitors that can overcome these resistance profiles.\\n\\n#### Genetic Link and Clinical Evidence\\nThe development of resistance to first-generation integrase inhibitors through mutations in the integrase gene itself provides a clear genetic link between the target and the disease. Clinical failure due to resistance has been documented, providing direct evidence of the target's role.\\n\\n#### Modulation Requirement\\nThe primary requirement for modulating this target is the inhibition of the integrase enzyme's ability to insert viral DNA into the host genome, thereby preventing viral replication.\\n\\n### Challenges for the Drug Discovery Program\\nDeveloping a new integrase inhibitor that is more potent and has a higher resistance barrier than dolutegravir involves addressing several challenges:\\n- **Resistance Mechanisms**: Understanding the structural mechanisms by which the virus develops resistance to integrase inhibitors is crucial.\\n- **Pharmacokinetics/Pharmacodynamics (PK/PD)**: Developing compounds with optimal PK/PD profiles that can be taken less frequently than current therapies.\\n- **Safety Profile**: Ensuring the new inhibitor does not induce unacceptable side effects.\\n- **IDA Strategy**: Investigating whether a structure-based drug design (information driven approach) could lead to the discovery of novel inhibitors that avoid known resistance mechanisms.\\n\\n#### RNA interference (RNAi) and small molecules\\nExploring other modes of action such as RNA interference (RNAi) could offer alternative ways to inhibit integrase expression. Small molecule inhibitors are the most extensively developed and studied, but peptide macrocycles, molecular glues, and PROTACs represent innovative approaches that could potentially address resistance issues.\\n\\n### Alternative Indications\\nShould the novel integrase inhibitors demonstrate unique properties, they could potentially be investigated for other retroviral infections where integrase plays a role, albeit detailed virological studies would be necessary to establish this potential.\\n\\nThe next step is to corroborate these points with relevant scientific literature using the use_pubmed_api function to ensure the accuracy and recency of the data supporting the target rationale for Integrase in HIV-1 infection. Let's proceed to gather the relevant literature next.\", 'name': 'SAR', 'role': 'user'}, {'content': '', 'tool_calls': [{'id': 'call_YspX38CNpD0yTImS74kryRXv', 'function': {'arguments': '{\"query\": \"HIV integrase inhibitors resistance\"}', 'name': 'use_pubmed_api'}, 'type': 'function'}, {'id': 'call_fv8qsMV9oe1jYI1gcH5aPI8e', 'function': {'arguments': '{\"query\": \"Clinical impact of new HIV integrase inhibitors\"}', 'name': 'use_pubmed_api'}, 'type': 'function'}], 'name': 'SAFEA', 'role': 'assistant'}, {'content': \"Title: Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV/AIDS Center in NE Romania.\\nAuthors: Loghin II, Rusu ȘA, Vâţă A, Cobaschi M, Cecan I, Manciuc C, Dorobăţ CM\\nJournal: Medicina (Kaunas, Lithuania), 2024\\nDOI: 10.3390/medicina60060854\\nAbstract: <i>Background and Objectives</i>: Antiretroviral therapy (ART) has revolutionized the management of HIV infection, transforming it from a once-debilitating disease to a chronic, manageable condition. ...\\n\\nTitle: High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.\\nAuthors: Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E\\nJournal: PloS one, 2024\\nDOI: 10.1371/journal.pone.0305129\\nAbstract: In 2019, WHO recommended dolutegravir (DTG) as a backbone for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). According to the 2018 Uganda's HIV treatm...\\n\\nTitle: Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1.\\nAuthors: Giammarino F, Sönnerborg A, Ceña-Diez R\\nJournal: Frontiers in cellular and infection microbiology, 2024\\nDOI: 10.3389/fcimb.2024.1334126\\nAbstract: The naturally occurring dipeptide Tryptophylglycine (WG) is enhanced in human immunodeficiency virus (HIV-1) infected Elite Controllers (EC). We have shown that this dipeptide has an anti-HIV-1 effect...\\n\\nTitle: A review of dolutegravir-associated weight gain and secondary metabolic comorbidities.\\nAuthors: Jemal M\\nJournal: SAGE open medicine, 2024\\nDOI: 10.1177/20503121241260613\\nAbstract: Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations. Excess...\\n\\nTitle: HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.\\nAuthors: Capeau J, Lagathu C, Ngono Ayissi K, Fève B, Béréziat V\\nJournal: Annales d'endocrinologie, 2024\\nDOI: 10.1016/j.ando.2024.05.005\\nAbstract: HIV infection has been controlled only since the introduction of triple therapy in 1996, combining, as antiretroviral agents, two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease i...\\n\\nTitle: Clinical considerations when switching antiretroviral therapy.\\nAuthors: Fernández A, Imaz A\\nJournal: Expert review of clinical pharmacology, 2024\\nDOI: 10.1080/17512433.2024.2365826\\nAbstract: Antiretroviral therapy (ART) can be personalized through simple formulations with high resistance barriers, favorable safety profiles, and novel administration routes. Switching treatments has become ...\\n\\nTitle: Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.\\nAuthors: West RE, Oberly PJ, Saylor AJ, Riddler SA, Nolin TD, Devanathan AS\\nJournal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024\\nDOI: 10.1016/j.jchromb.2024.124164\\nAbstract: Although antiretroviral therapy (ART) is highly effective for the treatment of HIV-1 infection to suppress virus in the blood, HIV persists in tissues. HIV persistence in the tissues is due to numerou...\\n\\nTitle: Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.\\nAuthors: Karabay O\\nJournal: AIDS (London, England), 2024\\nDOI: 10.1097/QAD.0000000000003885\\nAbstract: No abstract available...\\n\\nTitle: <i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.\\nAuthors: Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C, Lermechain F, Plantier J-C, Alessandri-Gradt E\\nJournal: Microbiology spectrum, 2024\\nDOI: 10.1128/spectrum.03895-23\\nAbstract: The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical...\\n\\nTitle: Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.\\nAuthors: Dekker JG, Klaver B, Berkhout B, Das AT\\nJournal: Journal of virology, 2024\\nDOI: 10.1128/jvi.00335-24\\nAbstract: No abstract available...\\n\\nTitle: Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.\\nAuthors: Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, Crusells-Canales M, Sierra JO, DeMoor R, Scherzer J, Ait-Khaled M, Bontempo G, Gill M, Patel N, D'Amico R, Hove K, Baugh B, Barnes N, Hadi M, Low EL, Anand SB, Hamilton A, Garges HP, Czarnogorski M\\nJournal: Journal of the International AIDS Society, 2024\\nDOI: 10.1002/jia2.26243\\nAbstract: Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long-acting (LA) regimen recommended for maintaining HIV-1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in...\\n\\nTitle: Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.\\nAuthors: Fletcher L, Burrowes S, Sabin LL, McCann N, Khan GK, Ruiz-Mercado G, Johnson S, Kimmel SD, Pierre C, Drainoni ML\\nJournal: AIDS patient care and STDs, 2024\\nDOI: 10.1089/apc.2024.0048\\nAbstract: Long-acting injectable (LAI) antiretroviral therapy (ART) has the potential to change the lives of people living with HIV (PLWH). To ensure equitable access to new treatment modalities, we examined th...\\n\\nTitle: Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.\\nAuthors: Wohlfeiler MB, Brunet L, Cochran Q, Fusco JS, Hsu RK, Fusco GP\\nJournal: Journal of the International Association of Providers of AIDS Care, 2024\\nDOI: 10.1177/23259582241245223\\nAbstract: We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB\\u2009+\\u2009RPV LAI) monthly injections schedule....\\n\\nTitle: Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture.\\nAuthors: McMullan HM, Gansemer BM, Thayer SA\\nJournal: Frontiers in pharmacology, 2024\\nDOI: 10.3389/fphar.2024.1369757\\nAbstract: <b>Introduction:</b> Antiretroviral (ARV) drugs have improved prognoses for people living with HIV. However, HIV-associated neurocognitive disorders (HAND) persist despite undetectable viral loads. So...\\n\\nTitle: Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.\\nAuthors: Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A, Unknown\\nJournal: BMJ open, 2024\\nDOI: 10.1136/bmjopen-2023-080606\\nAbstract: The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). K...\\n\\nTitle: Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.\\nAuthors: Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R, Unknown\\nJournal: Clinical pharmacokinetics, 2023\\nDOI: 10.1007/s40262-023-01289-5\\nAbstract: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to ...\\n\\nTitle: Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.\\nAuthors: Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, Günthard HF, Zangerle R, Smith C, Castagna A, d'Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, Fontas E, González E, Wasmuth JC, Sönnerborg A, De Wit S, Chkhartishvili N, Stephan C, Petoumenos K, Jaschinski N, Vannappagari V, Gallant J, Young L, Volny Anne A, Greenberg L, Martín-Iguacel R, Poveda E, Llibre JM, Unknown\\nJournal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023\\nDOI: 10.1093/cid/ciad219\\nAbstract: There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluat...\\n\\nTitle: Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.\\nAuthors: Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, McCauley M, Rinehart AR, St Clair M, Ford SL, Rooney JF, Adeyeye A, Chariyalertsak S, Mayer K, Arduino RC, Cohen MS, Grinsztejn B, Hanscom B, Landovitz RJ, Eshleman SH\\nJournal: Antimicrobial agents and chemotherapy, 2023\\nDOI: 10.1128/aac.00053-23\\nAbstract: HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have s...\\n\\nTitle: From Capillary Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using In Vitro Diagnostic (IVD) Assays and Software.\\nAuthors: Mohamed S, Boulmé R, Sayada C\\nJournal: Viruses, 2023\\nDOI: 10.3390/v15020571\\nAbstract: Drug-resistance mutations were mostly detected using capillary electrophoresis sequencing, which does not detect minor variants with a frequency below 20%. Next-Generation Sequencing (NGS) can now det...\\n\\nTitle: Cabotegravir Exposure of Zebrafish (<i>Danio rerio</i>) Embryos Impacts on Neurodevelopment and Behavior.\\nAuthors: Zizioli D, Zanella I, Mignani L, Degli Antoni M, Castelli F, Quiros-Roldan E\\nJournal: International journal of molecular sciences, 2023\\nDOI: 10.3390/ijms24031994\\nAbstract: As most new medications, Cabotegravir (CAB) was recently approved as an antiretroviral treatment of HIV infection without in-depth safety information on in utero exposure. Although no developmental to...\", 'tool_responses': [{'tool_call_id': 'call_YspX38CNpD0yTImS74kryRXv', 'role': 'tool', 'content': \"Title: Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV/AIDS Center in NE Romania.\\nAuthors: Loghin II, Rusu ȘA, Vâţă A, Cobaschi M, Cecan I, Manciuc C, Dorobăţ CM\\nJournal: Medicina (Kaunas, Lithuania), 2024\\nDOI: 10.3390/medicina60060854\\nAbstract: <i>Background and Objectives</i>: Antiretroviral therapy (ART) has revolutionized the management of HIV infection, transforming it from a once-debilitating disease to a chronic, manageable condition. ...\\n\\nTitle: High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.\\nAuthors: Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E\\nJournal: PloS one, 2024\\nDOI: 10.1371/journal.pone.0305129\\nAbstract: In 2019, WHO recommended dolutegravir (DTG) as a backbone for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). According to the 2018 Uganda's HIV treatm...\\n\\nTitle: Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1.\\nAuthors: Giammarino F, Sönnerborg A, Ceña-Diez R\\nJournal: Frontiers in cellular and infection microbiology, 2024\\nDOI: 10.3389/fcimb.2024.1334126\\nAbstract: The naturally occurring dipeptide Tryptophylglycine (WG) is enhanced in human immunodeficiency virus (HIV-1) infected Elite Controllers (EC). We have shown that this dipeptide has an anti-HIV-1 effect...\\n\\nTitle: A review of dolutegravir-associated weight gain and secondary metabolic comorbidities.\\nAuthors: Jemal M\\nJournal: SAGE open medicine, 2024\\nDOI: 10.1177/20503121241260613\\nAbstract: Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations. Excess...\\n\\nTitle: HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.\\nAuthors: Capeau J, Lagathu C, Ngono Ayissi K, Fève B, Béréziat V\\nJournal: Annales d'endocrinologie, 2024\\nDOI: 10.1016/j.ando.2024.05.005\\nAbstract: HIV infection has been controlled only since the introduction of triple therapy in 1996, combining, as antiretroviral agents, two nucleoside reverse transcriptase inhibitors (NRTIs) and one protease i...\\n\\nTitle: Clinical considerations when switching antiretroviral therapy.\\nAuthors: Fernández A, Imaz A\\nJournal: Expert review of clinical pharmacology, 2024\\nDOI: 10.1080/17512433.2024.2365826\\nAbstract: Antiretroviral therapy (ART) can be personalized through simple formulations with high resistance barriers, favorable safety profiles, and novel administration routes. Switching treatments has become ...\\n\\nTitle: Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.\\nAuthors: West RE, Oberly PJ, Saylor AJ, Riddler SA, Nolin TD, Devanathan AS\\nJournal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024\\nDOI: 10.1016/j.jchromb.2024.124164\\nAbstract: Although antiretroviral therapy (ART) is highly effective for the treatment of HIV-1 infection to suppress virus in the blood, HIV persists in tissues. HIV persistence in the tissues is due to numerou...\\n\\nTitle: Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.\\nAuthors: Karabay O\\nJournal: AIDS (London, England), 2024\\nDOI: 10.1097/QAD.0000000000003885\\nAbstract: No abstract available...\\n\\nTitle: <i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.\\nAuthors: Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C, Lermechain F, Plantier J-C, Alessandri-Gradt E\\nJournal: Microbiology spectrum, 2024\\nDOI: 10.1128/spectrum.03895-23\\nAbstract: The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical...\\n\\nTitle: Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.\\nAuthors: Dekker JG, Klaver B, Berkhout B, Das AT\\nJournal: Journal of virology, 2024\\nDOI: 10.1128/jvi.00335-24\\nAbstract: No abstract available...\"}, {'tool_call_id': 'call_fv8qsMV9oe1jYI1gcH5aPI8e', 'role': 'tool', 'content': \"Title: Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.\\nAuthors: Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, Crusells-Canales M, Sierra JO, DeMoor R, Scherzer J, Ait-Khaled M, Bontempo G, Gill M, Patel N, D'Amico R, Hove K, Baugh B, Barnes N, Hadi M, Low EL, Anand SB, Hamilton A, Garges HP, Czarnogorski M\\nJournal: Journal of the International AIDS Society, 2024\\nDOI: 10.1002/jia2.26243\\nAbstract: Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long-acting (LA) regimen recommended for maintaining HIV-1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in...\\n\\nTitle: Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.\\nAuthors: Fletcher L, Burrowes S, Sabin LL, McCann N, Khan GK, Ruiz-Mercado G, Johnson S, Kimmel SD, Pierre C, Drainoni ML\\nJournal: AIDS patient care and STDs, 2024\\nDOI: 10.1089/apc.2024.0048\\nAbstract: Long-acting injectable (LAI) antiretroviral therapy (ART) has the potential to change the lives of people living with HIV (PLWH). To ensure equitable access to new treatment modalities, we examined th...\\n\\nTitle: Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.\\nAuthors: Wohlfeiler MB, Brunet L, Cochran Q, Fusco JS, Hsu RK, Fusco GP\\nJournal: Journal of the International Association of Providers of AIDS Care, 2024\\nDOI: 10.1177/23259582241245223\\nAbstract: We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB\\u2009+\\u2009RPV LAI) monthly injections schedule....\\n\\nTitle: Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture.\\nAuthors: McMullan HM, Gansemer BM, Thayer SA\\nJournal: Frontiers in pharmacology, 2024\\nDOI: 10.3389/fphar.2024.1369757\\nAbstract: <b>Introduction:</b> Antiretroviral (ARV) drugs have improved prognoses for people living with HIV. However, HIV-associated neurocognitive disorders (HAND) persist despite undetectable viral loads. So...\\n\\nTitle: Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.\\nAuthors: Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A, Unknown\\nJournal: BMJ open, 2024\\nDOI: 10.1136/bmjopen-2023-080606\\nAbstract: The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). K...\\n\\nTitle: Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.\\nAuthors: Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R, Unknown\\nJournal: Clinical pharmacokinetics, 2023\\nDOI: 10.1007/s40262-023-01289-5\\nAbstract: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to ...\\n\\nTitle: Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.\\nAuthors: Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, Günthard HF, Zangerle R, Smith C, Castagna A, d'Arminio Monforte A, Wit F, Stecher M, Lehman C, Mussini C, Fontas E, González E, Wasmuth JC, Sönnerborg A, De Wit S, Chkhartishvili N, Stephan C, Petoumenos K, Jaschinski N, Vannappagari V, Gallant J, Young L, Volny Anne A, Greenberg L, Martín-Iguacel R, Poveda E, Llibre JM, Unknown\\nJournal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023\\nDOI: 10.1093/cid/ciad219\\nAbstract: There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluat...\\n\\nTitle: Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.\\nAuthors: Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, McCauley M, Rinehart AR, St Clair M, Ford SL, Rooney JF, Adeyeye A, Chariyalertsak S, Mayer K, Arduino RC, Cohen MS, Grinsztejn B, Hanscom B, Landovitz RJ, Eshleman SH\\nJournal: Antimicrobial agents and chemotherapy, 2023\\nDOI: 10.1128/aac.00053-23\\nAbstract: HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have s...\\n\\nTitle: From Capillary Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using In Vitro Diagnostic (IVD) Assays and Software.\\nAuthors: Mohamed S, Boulmé R, Sayada C\\nJournal: Viruses, 2023\\nDOI: 10.3390/v15020571\\nAbstract: Drug-resistance mutations were mostly detected using capillary electrophoresis sequencing, which does not detect minor variants with a frequency below 20%. Next-Generation Sequencing (NGS) can now det...\\n\\nTitle: Cabotegravir Exposure of Zebrafish (<i>Danio rerio</i>) Embryos Impacts on Neurodevelopment and Behavior.\\nAuthors: Zizioli D, Zanella I, Mignani L, Degli Antoni M, Castelli F, Quiros-Roldan E\\nJournal: International journal of molecular sciences, 2023\\nDOI: 10.3390/ijms24031994\\nAbstract: As most new medications, Cabotegravir (CAB) was recently approved as an antiretroviral treatment of HIV infection without in-depth safety information on in utero exposure. Although no developmental to...\"}], 'name': 'TAG', 'role': 'tool'}, {'content': '', 'role': 'assistant'}, {'content': \"Thank you, SAR, for the detailed scientific rationale outline. The references provided by the use_pubmed_api function should efficiently bolster the arguments and data laid out in the rationale.\\n\\nNow, let's proceed with the next task. TAG, it's your turn to develop and outline the comprehensive 1-year Target Assessment to Lead Identification (TA-LI) plan for the drug target 'Integrase' in the context of HIV-1 infection. Please also utilize the use_pubmed_api function to enrich your report with relevant literature.\", 'name': 'Moderator', 'role': 'user'}, {'content': \"Thank you, Moderator. I will now proceed with outlining the 1-year Target Assessment to Lead Identification (TA-LI) plan for Integrase in HIV-1 infection.\\n\\n### Target Assessment to Lead Identification (TA-LI) Plan for Integrase\\n\\n**1. Initial Assessment and Rationale**\\n   - **Inflection Points**: Immediate focus on assessing the existing and emergent resistance profiles against current integrase inhibitors, especially dolutegravir. This early assessment will guide the necessity and direction of novel inhibitor designs.\\n   - **Unmet Needs**: Although existing integrase inhibitors are effective, issues like viral resistance and long-term side effects persist, presenting an unmet need for more efficacious and safer interventions.\\n\\n**2. Status of In-Vitro Platforms**\\n   - Currently, several robust in vitro platforms are available for studying HIV integrase activity, including biochemical assays for enzyme inhibition and cellular assays using viral replication in host cells.\\n   - **Actions Needed**: Enhancements are necessary in high-throughput screening platforms to quickly evaluate the potency of novel compounds against a broader range of viral genetic variants.\\n\\n**3. Translational In Vivo Models**\\n   - **Current Models**: Mouse models engineered to produce human T cells (Hu-mouse models), allowing for an assessment of antiviral efficacy in a living system.\\n   - **Development Needs**: There's a need to establish more sophisticated models that can mimic drug resistance mechanisms observed in humans more accurately.\\n\\n**4. Tractability and Drug Development Challenges**\\n   - **Tractability**: HIV integrase is a proven druggable target with multiple approved inhibitors, confirming the feasibility of targeting this protein.\\n   - **Challenges**: The major challenges include overcoming the drug resistance that evolves rapidly due o the high mutation rate of HIV and ensuring the brain penetration of the inhibitors to address HIV-associated neurocognitive disorders.\\n\\n**5. Biomarkers and Readouts**\\n   - **Efficacy Biomarkers**: Viral load and integration site diversity can serve as direct biomarkers for evaluating the efficacy of integrase inhibitors.\\n   - **Target Engagement**: Indicators of drug-target interaction and engagement would primarily include the reduction in the integration of viral DNA into the host genome, which can be quantified using novel genomic techniques.\\n\\n**6. Commercial Viability**\\n   - Given the ongoing global burden of HIV, an effective integrase inhibitor would have significant commercial potential, particularly if it can offer advantages over existing therapies in terms of efficacy, safety, resistance management, or dosing convenience.\\n\\n**7. Milestones for the Next 1-Year**\\n   - **Q1-Q2**: Complete a comprehensive literature review and gap analysis on existing knowledge about HIV integrase, focusing on resistance mechanisms.\\n   - **Q3**: Establish partnerships for advanced genomic and proteomic studies to enhance understanding of integrase function and its interaction with inhibitors.\\n   - **Q4**: Initiate proof-of-concept studies using lead compounds in advanced in vivo models.\\n\\nTo support this plan, I will use the use_pubmed_api function to find relevant literature that provides recent advancements and existing gaps in the knowledge concerning HIV integrase inhibitors.\\n\\n**Requesting Literature Retrieval**\\nI will now request the retrieval of relevant scientific literature to support this TA-LI plan further.\", 'tool_calls': [{'id': 'call_CQKpwlbsl6iKuUSRB5weUZF6', 'function': {'arguments': '{\"query\":\"advancements in HIV integrase inhibitors\"}', 'name': 'use_pubmed_api'}, 'type': 'function'}], 'name': 'SAR', 'role': 'assistant'}, {'content': 'Title: Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.\\nAuthors: Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF\\nJournal: Journal of the International AIDS Society, 2024\\nDOI: 10.1002/jia2.26268\\nAbstract: Recent evidence has raised questions about whether newer HIV treatment regimens, including dolutegravir (DTG) and tenofovir alafenamide (TAF),\\xa0are associated with increases in blood pressure (BP)....\\n\\nTitle: Advances in HIV Management During Pregnancy and Infant Feeding.\\nAuthors: Espinal M, Yee LM, Fisher SA\\nJournal: Infectious disease clinics of North America, 2024\\nDOI: 10.1016/j.idc.2024.06.005\\nAbstract: Recent advances in human immunodeficiency virus (HIV) management during pregnancy and infant feeding encompass several key elements: expanded HIV testing guidance; growing evidence of safety, efficacy...\\n\\nTitle: Brief Histories of Retroviral Integration Research and Associated International Conferences.\\nAuthors: Grandgenett DP, Engelman AN\\nJournal: Viruses, 2024\\nDOI: 10.3390/v16040604\\nAbstract: The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes. Beca...\\n\\nTitle: D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15\\xa0years.\\nAuthors: Turkova A, Chan MK, Kityo C, Kekitiinwa AR, Musoke P, Violari A, Variava E, Archary M, Cressey TR, Chalermpantmetagul S, Sawasdichai K, Ounchanum P, Kanjanavanit S, Srirojana S, Srirompotong U, Welch S, Bamford A, Epalza C, Fortuny C, Colbers A, Nastouli E, Walker S, Carr D, Conway M, Spyer MJ, Parkar N, White I, Nardone A, Thomason MJ, Ferrand RA, Giaquinto C, Ford D, Unknown\\nJournal: Contemporary clinical trials, 2024\\nDOI: 10.1016/j.cct.2024.107540\\nAbstract: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of DTG/3TC in...\\n\\nTitle: Analysis of antiretroviral therapy interruption in people living with HIV during the 2010-2021 Period.\\nAuthors: Contreras-Macías E, Gutiérrez-Pizarraya A, Pineda-Vergara JA, Morillo-Verdugo R\\nJournal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2024\\nDOI: 10.1016/j.farma.2024.03.007\\nAbstract: In the context of the advancement of antiretroviral therapy and, as the characteristics of people living with HIV progress toward an aging population, understanding the causes of treatment interruptio...\\n\\nTitle: <i>Chicoric acid</i> advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway.\\nAuthors: Zhang W, Liu Y, Zhou J, Qiu T, Xie H, Pu Z\\nJournal: Clinical and experimental hypertension (New York, N.Y. : 1993), 2024\\nDOI: 10.1080/10641963.2024.2326021\\nAbstract: This study aimed to examine the impact of CA on DN and elucidate its underlying molecular mechanisms of inflammation....\\n\\nTitle: Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review.\\nAuthors: Azzman N, Gill MSA, Hassan SS, Christ F, Debyser Z, Mohamed WAS, Ahemad N\\nJournal: Reviews in medical virology, 2024\\nDOI: 10.1002/rmv.2529\\nAbstract: The discovery of anti-retroviral (ARV) drugs over the past 36\\xa0years has introduced various classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcripta...\\n\\nTitle: Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study.\\nAuthors: Brites C, Lacerda M, Sprinz E, Bay M, Pinto G, Azevedo P, Luz E, Lins-Kusterer L, Netto EM\\nJournal: Frontiers in medicine, 2024\\nDOI: 10.3389/fmed.2024.1302710\\nAbstract: Currently, integrase inhibitors (INIs)-based ART regimens are the preferred initial therapy for AIDS patients. There is scarce information on the use of dolutegravir (DTG) among late-presenter people ...\\n\\nTitle: Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV.\\nAuthors: Fisher SA, Madden N, Espinal M, Garcia PM, Jao JK, Yee LM\\nJournal: Clinical obstetrics and gynecology, 2024\\nDOI: 10.1097/GRF.0000000000000860\\nAbstract: Over the last 4 decades, significant advances in the care of HIV during pregnancy have successfully reduced, and nearly eliminated, the risk of perinatal HIV transmission. The baseline risk of transmi...\\n\\nTitle: Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors.\\nAuthors: Hikichi Y, Grover JR, Schäfer A, Mothes W, Freed EO\\nJournal: Science advances, 2024\\nDOI: 10.1126/sciadv.adn0042\\nAbstract: People living with human immunodeficiency virus (HIV) receiving integrase strand transfer inhibitors (INSTIs) have been reported to experience virological failure in the absence of resistance mutation...', 'tool_responses': [{'tool_call_id': 'call_CQKpwlbsl6iKuUSRB5weUZF6', 'role': 'tool', 'content': 'Title: Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.\\nAuthors: Manne-Goehler J, Fabian J, Sokhela S, Akpomiemie G, Rahim N, Lalla-Edward ST, Brennan AT, Siedner MJ, Hill A, Venter WDF\\nJournal: Journal of the International AIDS Society, 2024\\nDOI: 10.1002/jia2.26268\\nAbstract: Recent evidence has raised questions about whether newer HIV treatment regimens, including dolutegravir (DTG) and tenofovir alafenamide (TAF),\\xa0are associated with increases in blood pressure (BP)....\\n\\nTitle: Advances in HIV Management During Pregnancy and Infant Feeding.\\nAuthors: Espinal M, Yee LM, Fisher SA\\nJournal: Infectious disease clinics of North America, 2024\\nDOI: 10.1016/j.idc.2024.06.005\\nAbstract: Recent advances in human immunodeficiency virus (HIV) management during pregnancy and infant feeding encompass several key elements: expanded HIV testing guidance; growing evidence of safety, efficacy...\\n\\nTitle: Brief Histories of Retroviral Integration Research and Associated International Conferences.\\nAuthors: Grandgenett DP, Engelman AN\\nJournal: Viruses, 2024\\nDOI: 10.3390/v16040604\\nAbstract: The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes. Beca...\\n\\nTitle: D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15\\xa0years.\\nAuthors: Turkova A, Chan MK, Kityo C, Kekitiinwa AR, Musoke P, Violari A, Variava E, Archary M, Cressey TR, Chalermpantmetagul S, Sawasdichai K, Ounchanum P, Kanjanavanit S, Srirojana S, Srirompotong U, Welch S, Bamford A, Epalza C, Fortuny C, Colbers A, Nastouli E, Walker S, Carr D, Conway M, Spyer MJ, Parkar N, White I, Nardone A, Thomason MJ, Ferrand RA, Giaquinto C, Ford D, Unknown\\nJournal: Contemporary clinical trials, 2024\\nDOI: 10.1016/j.cct.2024.107540\\nAbstract: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of DTG/3TC in...\\n\\nTitle: Analysis of antiretroviral therapy interruption in people living with HIV during the 2010-2021 Period.\\nAuthors: Contreras-Macías E, Gutiérrez-Pizarraya A, Pineda-Vergara JA, Morillo-Verdugo R\\nJournal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2024\\nDOI: 10.1016/j.farma.2024.03.007\\nAbstract: In the context of the advancement of antiretroviral therapy and, as the characteristics of people living with HIV progress toward an aging population, understanding the causes of treatment interruptio...\\n\\nTitle: <i>Chicoric acid</i> advanced PAQR3 ubiquitination to ameliorate ferroptosis in diabetes nephropathy through the relieving of the interaction between PAQR3 and P110α pathway.\\nAuthors: Zhang W, Liu Y, Zhou J, Qiu T, Xie H, Pu Z\\nJournal: Clinical and experimental hypertension (New York, N.Y. : 1993), 2024\\nDOI: 10.1080/10641963.2024.2326021\\nAbstract: This study aimed to examine the impact of CA on DN and elucidate its underlying molecular mechanisms of inflammation....\\n\\nTitle: Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review.\\nAuthors: Azzman N, Gill MSA, Hassan SS, Christ F, Debyser Z, Mohamed WAS, Ahemad N\\nJournal: Reviews in medical virology, 2024\\nDOI: 10.1002/rmv.2529\\nAbstract: The discovery of anti-retroviral (ARV) drugs over the past 36\\xa0years has introduced various classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcripta...\\n\\nTitle: Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study.\\nAuthors: Brites C, Lacerda M, Sprinz E, Bay M, Pinto G, Azevedo P, Luz E, Lins-Kusterer L, Netto EM\\nJournal: Frontiers in medicine, 2024\\nDOI: 10.3389/fmed.2024.1302710\\nAbstract: Currently, integrase inhibitors (INIs)-based ART regimens are the preferred initial therapy for AIDS patients. There is scarce information on the use of dolutegravir (DTG) among late-presenter people ...\\n\\nTitle: Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV.\\nAuthors: Fisher SA, Madden N, Espinal M, Garcia PM, Jao JK, Yee LM\\nJournal: Clinical obstetrics and gynecology, 2024\\nDOI: 10.1097/GRF.0000000000000860\\nAbstract: Over the last 4 decades, significant advances in the care of HIV during pregnancy have successfully reduced, and nearly eliminated, the risk of perinatal HIV transmission. The baseline risk of transmi...\\n\\nTitle: Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors.\\nAuthors: Hikichi Y, Grover JR, Schäfer A, Mothes W, Freed EO\\nJournal: Science advances, 2024\\nDOI: 10.1126/sciadv.adn0042\\nAbstract: People living with human immunodeficiency virus (HIV) receiving integrase strand transfer inhibitors (INSTIs) have been reported to experience virological failure in the absence of resistance mutation...'}], 'name': 'SAFEA', 'role': 'tool'}, {'content': \"Thank you, TAG, for the comprehensive outline of the 1-year Target Assessment to Lead Identification (TA-LI) plan for Integrase in HIV-1 infection. The details you've provided, especially on milestones, key biomarkers, and global challenges, align well with the thorough strategy required for successful drug development.\\n\\nWith this TA-LI plan enriched by relevant data from the recent literature, including the advancements in HIV integrase inhibitors, we have an informed basis to proceed effectively.\\n\\nFinally, it's SAFEA's turn to perform the safety assessment for Integrase as a target in our drug discovery strategy. SAFEA, please assess the safety profile of targeting Integrase, taking into account tissue specificity, expression patterns, potential safety risks including immunogenicity, and any evidence of species differences that may influence translational models. Please utilize any required tools or data sources to substantiate your findings effectively.\", 'name': 'TAG', 'role': 'user'}, {'content': '', 'role': 'assistant'}, {'content': \"As the Moderator, it seems there was an oversight, and no specifics have been provided for the agents to proceed with their assigned tasks, particularly for SAFEA's task on the safety assessment for Integrase.\\n\\nNow, SAFEA, please conduct a thorough safety assessment of the proposed drug target Integrase, covering all aspects outlined earlier. This should include:\\n- Expression patterns and tissue specificity.\\n- Potential species differences impacting translational models.\\n- On-target and off-target safety concerns.\\n- Risks associated with exaggerated pharmacology, such as potential immunogenicity concerns.\\n- The potential for modulation of the target to promote tumor formation or other serious side effects.\\n\\nPlease ensure to reference any relevant literature and data to support your safety profile conclusions. If necessary, use appropriate functions like use_pubmed_api to retrieve the most up-to-date and relevant information. Proceed when ready, SAFEA.\", 'name': 'Moderator', 'role': 'user'}], summary=\"As the Moderator, it seems there was an oversight, and no specifics have been provided for the agents to proceed with their assigned tasks, particularly for SAFEA's task on the safety assessment for Integrase.\\n\\nNow, SAFEA, please conduct a thorough safety assessment of the proposed drug target Integrase, covering all aspects outlined earlier. This should include:\\n- Expression patterns and tissue specificity.\\n- Potential species differences impacting translational models.\\n- On-target and off-target safety concerns.\\n- Risks associated with exaggerated pharmacology, such as potential immunogenicity concerns.\\n- The potential for modulation of the target to promote tumor formation or other serious side effects.\\n\\nPlease ensure to reference any relevant literature and data to support your safety profile conclusions. If necessary, use appropriate functions like use_pubmed_api to retrieve the most up-to-date and relevant information. Proceed when ready, SAFEA.\", cost={'usage_including_cached_inference': {'total_cost': 0}, 'usage_excluding_cached_inference': {'total_cost': 0}}, human_input=[])"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "initialiser.initiate_chat(\n",
    "        manager,\n",
    "        message=\"\"\"You are a AI assistant with a background in drug discovery.\n",
    "\n",
    "    Given target: Integrase\n",
    "    Given disease: HIV 1 infection\n",
    "    Given mode of action: Dolutegravir is an HIV-1 antiviral agent. It inhibits HIV integrase by binding to the active site and blocking the strand transfer step of retroviral DNA integration in the host cell. The strand transfer step is essential in the HIV replication cycle and results in the inhibition of viral activity. Dolutegravir has a mean EC50 value of 0.5 nM (0.21 ng/mL) to 2.1 nM (0.85 ng/mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells.4\n",
    "\n",
    "    Context:\n",
    "    The current treatment for HIV-1 infection involves a combination of antiretroviral drugs to suppress viral replication and prevent the progression of the disease. Dolutegravir is a potent integrase inhibitor that has shown high efficacy in the treatment of HIV-1 infection. However, there is a need to develop a scientific rationale for the use of dolutegravir in the treatment of HIV-1 infection, highlighting the working hypothesis, clinical target rationale, and challenges for the drug discovery program related to the target.\n",
    "\n",
    "    Task 1: Develop a scientific rationale for Integrase in HIV 1 infection.\n",
    "\n",
    "    Highlight the working hypothesis for the clinical target rationale and human biology evidence by minimum 2000 words.\n",
    "\n",
    "    Describe as much as possible the evidence in humans or in human tissue that link the target, target space or approach to the pathogenesis of interest.\n",
    "    If known, also describe here the wanted mode of action with regards to desired clinical outcome.\n",
    "    Please avoid including only pre-clinical data in this section.\n",
    "\n",
    "    Use the following structure and provide a detailed description for each point:\n",
    "    - Working hypothesis:\n",
    "    - Create a detailed description of the following idea: Creating a new inhibitor for HIV-1 integrase that is more potent and has a higher barrier to resistance than dolutegravir.\n",
    "    - Is there are significant unmet medical need?\n",
    "    - Is it suitable for combination therapy?\n",
    "    - Which predictive biomarkers exist for the target related to the disease?\n",
    "        - Provide a detailed description of existing clinical relevant biomarkers.\n",
    "\n",
    "    - Clinical target rationale:\n",
    "    - How relevant is the target location to the disease biology?\n",
    "    - How it the target expression altered in human disease?\n",
    "    - How is the target involved in the physiological process relevant to the disease?\n",
    "    - Which phenotypes and genotypes were identified for the target?\n",
    "    - How is the genetic link between the target and the disease?\n",
    "    - Describe the evidence provided in clinics or by tools acting on the pathway where the target is involved.\n",
    "    - Which kind of target modulation is required to treat the disease?\n",
    "\n",
    "    - Challenges for the drug discovery program related to the target.\n",
    "    - Check the following idea for details on small molecule compounds: Creating a new inhibitor for HIV-1 integrase that is more potent and has a higher barrier to resistance than dolutegravir..\n",
    "    - Is a 'information driven approach' (IDA) strategy based on available small molecules possible?\n",
    "        - Which small molecular modulators of the target known?\n",
    "        - Which inhibitors, antagonists, agonists, negative allosteric modulators (NAM), positive allosteric modulators (PAM) are required for target modulation in the given disease? \n",
    "    - Which patients would respond the therapy?\n",
    "    - Is the proposed mode of action on the target desirable and commercially viable in a clinical setting?\n",
    "    - What are advantages and disadvantages of different therapeutic modalities (antibodies, small molecules, antisense oligonucleotides, PROTACs, molecular glue, peptide macrocycles, and so on) for tackling the target?\n",
    "\n",
    "    - Alternative indications:\n",
    "    - Describe alternative indication for modulators of the target and explain why.\n",
    "\n",
    "    Task 2: Develop a target assessment strategy for Integrase in HIV 1 infection in maximal 500 words.\n",
    "\n",
    "    Outline a 1-year Target Assessment (TA) to Lead Identification (LI) plan. Describe High Level TA-LI plans.\n",
    "    - Make an emphasis on key inflection points that will inform the feasibility of the project. \n",
    "    - Address status of in-vitro platforms, translational in vivo models (mechanistic models, not necessarily so called 'disease models')\n",
    "    and describe what needs to be established. Elaborate on tractability and major challenges for advancement in a drug discovery portfolio.\n",
    "    - Discuss potential biomarkers and readouts for efficacy and target engagement.\n",
    "\n",
    "    Task 3: Safety assessment\n",
    "    - Does the target show bias towards expression in the desired organ (e.g. CNS)?\n",
    "    - Is it specifically expressed in the organ (e.g. brain)?\n",
    "    - Are there disease specific expression databases?\n",
    "    - Are there tissue-selective isoforms of the target?\n",
    "    - Are there condition-specific isoforms of the target?\n",
    "    - What regulates the alternative splicing that makes one isoform versus the other?\n",
    "    - How large is the expression of the target in the mouse model intended for in vivo tests?\n",
    "    - Is major phenotype reported in target knockouts and/or expression of rodent models?\n",
    "    - Are there published differences in expression between human and rodent models.\n",
    "    - What are the species differences that could be used to interpret rodent safety data on the target?\n",
    "    - What are the peripherial safety risks (oncogensis)?\n",
    "    - Can the modulation of the target promote tumor formation?\n",
    "    - Is there a way to assess on-target safety concerns?\n",
    "    - What are the safety concerns in case of exaggerated pharmacology?\n",
    "    - Will it disrupt cellular functions (e.g. endosomes, lysosomes, nuclear, mitochondrial) function with all its safety liability?\n",
    "    - How large is the risk for immunogenicity (related to biologics/antibody based approaches)?\n",
    "    - If the target is an enzyme, do polymorphisms in the human gene alter the protein enzyme activity?\n",
    "\n",
    "    Provide the corresponding literature references in the format (First author, Journal, Year, Volume, Issue, Pages, DOI). If any are missing or not available, please mark as N/A.\n",
    "\n",
    "    Let's work this out in a step by step way to be sure we have the right answer.\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "You are an expert in drug discovery and clinical target rationale. Your role is to develop a comprehensive scientific rationale for the given target in the specified disease. You will:\n",
    "                    Formulate a working hypothesis based on the provided information.\n",
    "                    Analyze the clinical target rationale, focusing on human biology evidence.\n",
    "                    Evaluate the relevance of the target to the disease and its physiological processes.\n",
    "                    Assess genetic links, phenotypes, and clinical evidence related to the target.\n",
    "                    Identify challenges in the drug discovery program for this target.\n",
    "                    Suggest alternative indications for target modulators.\n",
    "                    Use the use_pubmed_api function to find and cite relevant scientific literature.\n",
    "                    Ensure your response covers all points requested in the prompt, with a minimum of 2000 words for the main rationale.\n",
    "\n",
    "\"\"\",\n",
    "        clear_history=True\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'autogen.agentchat.chat.ChatResult'>\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "LLM_agent",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
